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An oral Vibrio vaccine for salmonids was developed.
The vaccine was produced by spray coating lyophilized
formalin-killed whole cells of Vibrio anguillarum (VA LS 1-
74) onto non-pareil sugar beads.Then methacrylic acrylic
acid copolymer (Eudragit L-30D) was applied as an enteric
protective coating.
Using x-ray radiographic techniques, it was found that
large particles (> 1.1 mm) remain in the fish stomach for
more than 2 hours before they would enter thepyloric caeca.
The pyloric sphincter which has an opening of 0.94 mm, acts
as barrier to prevent the passage of large foodparticles in
the stomach to the pyloric caeca.Based on this information
non-pareil sugar beads of 18-20 mesh or smaller should be
used as the vaccine carriers.A 15% (w/w) Eudragit L-30D
coating is needed to provide enteric protection of the
vaccine loaded sugar beads of 18-20 mesh size.Lower levels
of coating resulted in the bead breaking down in the stomach
and releasing contents prior to entering the pyloric caeca.Since the lymphoid tissues are diffuse throughout the whole
GI tract, it may not be necessary to target a vaccine to
deliver antigens to a specific area of the intestinal tract,
but only protect the antigens from gastric fluids.
In vitro dissolution studies indicate that 10% VA LS 1-
74 loading was sufficient for rapid vaccine release (42%
released in 30 minutes) and a 15% Eudragit L-30D coating was
suitable for providing protection against stomach acid.The
vaccine product used in vivo studies contained 10% VA LS 1-
74 and 15% Eudragit L-30D on non-pareil sugar seeds of 18-20
mesh size.
Coho salmon were given the vaccine orally, and 30 days
afterward a live challenge test was performed.There was no
significant difference in the survival rates in a live
bacteria challenge test with the positive control (83.3%)
and test (80.3%) groups.Both had higher survival rates
than the no vaccine fed control group.The serum and
mucosal antibody levels to Vibrio were significantly higher
(p<0.01) in the test group (19700 units/ml) than the other
two groups (2530 units/ml in the positive control group and
617 units/ml in the negative control group).The antibody
titer appears to be a better indicator for vaccine efficacy
than survival rate of live bacteria challenge tests.
The oral Vibrio vaccine developed is effective, and the
technique to protect the antigen can be applied to other
antigens or proteins for oral delivery producing an
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VIBRIO VACCINES
INTRODUCTION
Vaccination has always been chosen as the best way to
control an infectious disease in humans and fish.Most
vaccination methods involve injections while oral
vaccinations are not effective (Johnson et al. 1983).
Vibrio anguillarum was used as the model bacterial pathogen
and developed into an orally active vaccine against
vibriosis in salmonids.Chapter I of the thesis focuses on
the physiological aspects of the fish gut and the
requirements needed for the antigen to reach the site of GI
tract where it can interact with the immune system.Chapter
II discusses the formulation procedure and results of
dissolution of vaccine products.Chapter III includes an in
vivo challenge of live bacteria and measurement of antibody
levels after administering the vaccine to conclude the
effectiveness of the oral Vibrio vaccine.2
CHAPTER I
GI TRANSIT TIMES AND PHYSIOLOGY OF SALMONID
GASTROINTESTINAL TRACT3
ABSTRACT
Histological staining of the coho salmon (Oncoryhnchus
kisutch) GI tract revealed diffuse lymphoid tissues
throughout the whole length of the GI tract.The pH of the
stomach was found to be very acidic (pH 3.7 + 1.2).Barium
sulfate suspension stayed in the stomach for up to 2 hours
and traveled throughout the length of the GI tract.After
eight hours, most barium sulfate resided in the lower
intestine.The opening of the pyloric sphincter of Coho
salmon (mass 50-80 g) was measured to be 0.94 mm + 0.10 mm.
Vaccine beads coated with enteric coating of 15% w/w
(methacrylic acrylic acid copolymer) and larger than 1.1 mm
did not pass through the pyloric sphincter but stayed in the
stomach for seven hours.Sugar beads of size 18-20 mesh
(1.00 + 0.06 mm) or smaller passed through the pyloric
sphincter and are suitable carriers of the oral Vibrio
vaccine.A 15% (w/w) methacrylic acrylic acid copolymer
(Eudragit L-30D) enteric coating should be sprayed on top
for enteric protection against the acidity of the fish
stomach.Lower levels of coating with methacrylic acrylic
acid copolymer break down in the stomach and release their
contents there.4
INTRODUCTION
To develop a successful oral vaccine, familiarity with
the physiology, immunology and current vaccination practices
is necessary.In fish there are two types of specific or
adaptive immune responses characterized by antibody
production (humoral immunity) and involvement of lymphocytes
(cell mediated immunity, CMI).The sites of protective
immunity can be found either systemically within the tissues
of the body, (especially the organs of phagocytic filtration
like kidney or spleen) or in integumentary organs like gut,
gills and skin.It is very important that a vaccine
stimulates both systemic and integumentary immune systems to
offer maximum protection (1).
Intraperitoneal (i.p.) injection can stimulate the
systemic immune response and was the first reported
effective immunization method against vibriosis (2).
However, disadvantages of i.p. injection of vaccines include
intensive labor to administer, stress caused by handling and
anesthesia, and a size limitation of the fish as it is only
feasible to inject fish of 15 g and larger.
Although most of the current vaccines are administered
by the method of immersion, researchers began with
hyperosmotic immersion (3,4).Hyperosmotic immersion
involves the immersion of fish in a hypertonic saline
solution for a short time followed by a dip in an aqueous
solution of the vaccine.The concept was that fish would5
lose water when placed in the hypertonic salt solution and
would take the water back up together with extensive amounts
of vaccine when the fish was later placed in the vaccine
solution.This vaccination method induces considerable
stress on fish and it was quickly realized that direct
immersion in the vaccine was equally efficacious (5).
Direct immersion involves dilution of the vaccine (usually 1
to 10 of most commercial vaccines), removal of the fish from
the tanks, immersion of the fish in the vaccine solution for
up to 30 seconds, draining of excessvaccine and returning
of the fish to their tanks.This type of handling procedure
can still be stressful to the fish and suppresstheir immune
response to the vaccine (6).
The idea of simply feeding the vaccine together with
the feed during routine husbandry is very attractive.It is
a suitable method of vaccination forfish of any size and
saves a lot of labor, time, and costs.It is also non-
stressful to the fish.Oral vaccination was the first mass
immunization method used with fish but it was not very
effective (7).Theoretically, with oral vaccination both
the integumentary (skin, gill and intestine) and the
systemic immune response can be stimulated when the vaccine
passes through the gastrointestinal tractand is absorbed
into the blood stream (1).Oral administration of vaccine
stimulating both integumentary and systemic immunity is
especially important because experimentally induced
infection by water-borne exposure demonstrated Vibrio6
anquillarum (as well as Aeromonas salmonicida) enter the
fish by penetrating the descending intestine and rectum
while Vibrio ordalii can enter by penetrating the skin (8).
To fully understand how an immune response is elicited
during oral vaccination, a basic knowledge of fish
immunology and physiology of the gastrointestinal tract must
be known.Important factors like GI transit times, the
relationship between particle size and GI transit, pH's of
the various segments of gut and the relationship of pH to
antigen uptake during the digestive process should also be
considered.
In mammals the gut-associated lymphoid tissue, in
particular the Peyers' patches, plays an important role in
the immunological defense against pathogens entering the
gastrointestinal tract (9).Antigens enter from the
intestinal lumen via specialized epithelium M cells across
conventional absorptive cells and stimulate lymphocytes
within Peyer's patches, which then migrate to mesenteric
nodes for further maturation.After maturation these
lymphocytes enter the systemic circulation as plasmablasts
to redistribute along intestinal mucosal surfaces and
produce secretory IgA antibodies.
In other vertebrates like reptiles and urodeles,
lymphoid aggregates are also present in the gut (10,11).In
carp, many scattered lymphoid-like cells are present in the
epithelium and lamina propria although no aggregates are
found (12).The hindgut of most teleosts contains a gut7
segment that seems to specialize in the uptake and
processing of antigens (13-20).At least a part of
intubated antigens finally appear in intraepithelial
macrophages of the second gut segment of carp (21,22).
Enterocytes in the second gut segment of carp may be
functional analogues of mammalian M cells.
Using immunocytochemical and electron-microscopy
techniques, uptake and transport of soluble (ferritin) and
particulate (Vibrio anguillarum) antigens from intestinal
lumen to mucosal macrophages was studied by Rombout et al.
(23).Both ferritin and Vibrio anguillarum were shown to be
taken up by epithelial cells of the second gut segment,
entrapped in supranuclear vacuoles and finally transported
to large intraepithelial macrophages (23).After anal
intubation of ferritin and Vibrio anguillarum, many small
macrophages penetrate the intestinal epithelium and take up
the antigens (23).However, these small macrophages
disappear from the intestinal mucosa after 24 hours and
similar events can be observed after anal saline intubation.
Larger and less mobile macrophages stay in the intestinal
epithelium and finally expose antigenic determinants of both
ferritin and Vibrio anguillarum at their outer surface.
This suggests an antigen-presenting function.These larger
macrophages stay in the epithelium and may induce a local or
mucosal response while small mobile macrophages may induce a
systemic response (23).
Although macrophages dominate the epithelium of the8
second gut segment of carp, basophilic and eosinophilic
granulocytes are mainly found in the connective tissue of
the first gut segment (24).Applying monoclonal antibodies
against serum immunoglobulin (Ig) in an immuno-gold
technique, only a small number of lymphoid cells appear to
be Ig-immunoreactive at their external membrane.This
suggests the presence of many more T than B cells in the
intestinal mucosa.Plasma cells with Ig-immunoreactive
cytoplasm can frequently be found in the head portion of the
carp kidney while plasma cells with an Ig-immunoreactive
cytoplasm are scarce in the intestinal mucosa.As mucosa
plasma cells can regularly be found with electron
microscopy, they possibly contain another class of Ig type
antibody.On the other hand, macrophages and monocyte-like
cells are found to be Ig-immunoreactive, suggesting the
presence of immune complexes at their external membrane
(24).The presence of antigen-presenting and immune
complex-binding macrophages together with the high number of
lymphocytes in the second gut segment of fish implies the
existence of a local or mucosal immune system (24).
Anal immunization with Vibrio anguillarum can elicit
mucosal as well as serum responses (25).This suggests that
efficacy of oral vaccination can be improved by targeting
the delivery and release of the vaccine to the second gut
segment bypassing the stomach.The possibility exists that
the high acid concentration in the stomach may denature or
inactivate orally administered vaccines before they reach9
the second gut.
In 1907 the acidity of the elasmobranch stomach was
found by Sullivan (26) to be equivalent to 0.6% and 0.4% HC1
in the free and bound forms, respectively, and this acidity
increased markedly after feeding.Gastric acidity was once
thought to be due to an organic acid (27). Dobreff showed
that free HC1 was the form of acid present in the stomach
(28).Bayliss (29) has obtained the pH of the plaice
(Pleuronectes platessa) stomach by sampling either the
gastric juice or drops of water on the surface of an empty
stomach.The pH values range from 2.4 to 7.6 with a mean
value of 5.65.In 1929, Vonk (30) found the pH of Esox
stomach to be 4.5 to 4.7 and pointed out that the pH on the
food surface should be lower.By use of a capillary glass
electrode, the pH of the surface of a prey lying within the
stomach of an Esox was measured to be between 2.4 and 3.6
(31,32).At a depth of only 3 mm beneath the surface of the
prey, the pH increased rapidly to a value of 4.7.
Although the major antigen for protection against
Vibrio anguillarum is a lipopolysaccharide (33,34), most
active immunogens are proteins which degrade when subjected
to high acidic environment.To develop a potent oral
vaccine, the antigen must be protected from the high acid
environment in the stomach.
The goals of this part of the study were the
identification of any lymphoid aggregates along the whole10
gastrointestinal tract where vaccine delivery was to be
targeted, measurement of GI transit times using x-ray
radiography and determining the pH's in different segments
of the GI tract.The coating level of Eudragit L-30D for
protection of the vaccine from dissolving in the fish
stomach was identified.The size of pyloric sphincter was
measured to determine a suitable size of non-pareil sugar
seeds to be used as carriers of future oral vaccines.11
MATERIALS AND METHODS
Materials
Coho salmon (Oncorhynchus kisutch)
Coho salmon were donated by the Oregon State Department
of Fish and Wildlife (ODFW) and transferred to the Salmon
Disease Laboratory at Oregon State University.Each fish
weighed between 50 to 80 g.
Non-pareil sugar seeds'
Four different sizes of sugar seeds with mesh sizes 14-
16 (1.4 ± 0.2 mm), 18-20 (1.0 ± 0.06 mm),20-25 (0.85 ±
0.06 mm) and 25-30 (0.74 + 0.03 mm) were selected forthis
part of the study (table I.1).
X-ray apparatus and barium sulfate suspension for upper GI
The X-ray machine was a Transworld 325V Radiographic X-
ray system2.Its output can range from 50 to 300 mA
(milliAmperes) with a 125 KVP (Kilovolt Peak) maximum at all
mA ratings.Dupont Cronex HiPlus intensifying screens were
used together with Kodak XTL 8 x 10 films.
Barium sulfate suspension (72% w/v)3 for the upper GI
radiography was obtained commercially and contained
preservatives, suspending agents, natural and artificial
flavor and artificial sweeteners.12
Table 1.1Measurements of the Diameter of Eudragit L-30D
Coated Non-pareil Sugar Beads.
Level of Mesh Diametera Standard error
enteric coatingsize
(w/w%) (mm) (mm)
0 14-16 1.412 0.234
0 18-20 1.004 0.059
0 20-25 0.848 0.057
0 25-30 0.744 0.029
10 14-16 1.395 0.184
10 18-20 0.984 0.058
10 20-25 0.875 0.075
10 25-30 0.743 0.048
15 14-16 1.685 0.202
15 18-20 1.035 0.081
15 20-25 0.861 0.049
15 25-30 0.731 0.041
aaverage of 50 measurements13
Barium sulfate and Eudragit L-30 D loaded beads for GI
transit times study
Sugar beads of mesh size 18-20 (1.0 + 0.06 mm) were
coated with barium sulfate4 and bovine serum albumin4 to
yield a 40% (w/w) barium sulfate and 5% (w/w) bovine serum
albumin final sugar bead product.The spray coater was an
Aerocoat Strea-1 spray coater with a modified Lab-
line/P.R.L. High Speed Fluid Bed Dryers.Temperature was
set at 25°C (ambient temperature) and nozzle pressure was
maintained at 10 - 15 psi.A peristaltic pump6 was used to
deliver the coating solution 15% w/v that contained both
barium sulfate and BSA (8 parts by weight of barium sulfate
to 1 part by weight of BSA) at a rate of about 6 ml/minute.
Different amounts of methacrylic acrylic acid copolymer
(Eudragit L-30D7)(0%, 5%, 10% and 15 % w/w final bead
weight) were then spray-coated to serve as enteric coatings.
Plasticizers were 10%triethyl citrate (TEC)(w/w of dry
Eudragit) and 10% dibutylsebacate (DBS)(w/w of dry
Eudragit) (see table 1.2).The final Eudragit L-30D coating
solution had a concentration of about 20% w/v.Similar
coating conditions were used except the flow rate of coating
solution was reduced to about 2.8 ml/minute to avoid
clumping.Figures 1.1, 1.2 and table 1.3 show the size and
weight calibrations of these formulations.
Eudragit L-30D loaded sugar beads for pyloric sphincter size
determination14
Table 1.2Composition of Solution for Enteric Coating.
Eudragit L-"Da (30% lacquer)
Triethyl citrateb
Dibutyl sebacatec
H2O
Total
48.19 g
1.81 g
1.81 g
48.19 g
100 g
a Rohm Pharma, Waiterstadt, West Germany
b Aldrich Chemical Company, Inc., Milwaukee, Wisconsin,
U.S.A.
c Sigma Chemical Company, St. Louis, Missouri, U.S.A.00-'
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Figure 1.2
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Eudragit L-300 Coating Level
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The mass of barium loaded non-pareil sugar beads with
various levels of Eudragit L-30D (0, 5, 10 and 15%).
Each bead contains 40% (w/w) barium sulfate and 5% BSA.17
Table 1.3Measurements of the Diameter of 40% (w/w) Barium
Sulfate and 5% (w/w) Bovine Serum Albumin Loaded
Non-pareil 18-20 Mesh Sugar Beads.
Level of Diametera Standard error
enteric coating
(w/w %) (mm) (mm)
0 1.081 0.054
5 1.110 0.061
10 1.111 0.071
15 1.155 0.065
aaverage of 50 measurements18
Non-pareil sugar beads of different mesh sizes (14-30
mesh) were coated with either 10% or 15% Eudragit L-30D
under the same conditions as described above.The diameters
(0.74, 0.88, 0.98, 1.40, 0.73, 0.86 ,1.04, 1.69 mm) and
weights (0.30, 0.46, 0.70, 1.44, 0.30, 0.45, 0.72, 1.50 mg)
of each of these formulations were shown in figures 1.3 and
1.4, respectively.
Methods
Identification of lymphoid aggregates in GItract8
The whole fish gastrointestinal tract was isolated and
fixed in 10% neutral phosphate buffered formalin for 24-48
hours.The tissue was then embedded in paraffin and
sectioned with a microtome at 4 um thickness.After
staining with hematoxylin and eosin (H & E), a slide was
made and each slide was cover-slipped with permount.
Determination of the pH along the GI tract
Each fish was fasted for 48 hours and immediately
dissected after euthanasia.The pH in each segment of the
GI tract (stomach, pyloric caeca, upper intestine - 1 cm
from the pyloric caeca, lower intestine - 2 cm from the end
of anus) was determined by a surface-sensitive pHprobe9.
Other physical parameters including weight, total length of
fish, lengths of esophagus to end of stomach, pyloric caeca
and intestine were also recorded.A total of 22 fish were
used in this part of the study.1
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Mesh Size
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The mass of non-pareilsugar beads (14-16 M, 18-20 M,
20-25 M, 25-30 M) coated with variouslevels of Eudragit
L-30D (0, 10 and 15%)as an enteric coating.21
X-ray radiography on GI transit times
The settings on the X-ray machine were 300 milliAmperes
(mA) with a 0.1 second exposure time (or 30 milliAmperes-
second, mAs).The KVP was set at 46 and the focal film
distance kept constant at 36 inches.During the experiment
approximately 1 ml of barium sulfate suspension was given to
each fish by oral intubation using a micropipette (figure
1.5).X-ray film exposure was performed on each fish at 0
h, 2 h, 5 h,6 h and 8 h after administration of barium
sulfate suspension.
Determination of Eudragit L-30D thickness for enteric
protection against fish stomach acid
Eight fish were divided into four groups.The two fish
in each group were intubated with the same amount of 40%
barium sulfate (and 5% BSA) loaded sugar beads that contain
the same level of Eudragit L-30 D coating.The four
Eudragit coating levels were 0%, 5%, 10% and 15%.The same
micropipette method of administration as described above was
used for the vaccine beads and each of the dry sugar bead
formulations was mixed with minimal amount (about 1 ml) of
pH 4.5 phosphate buffer to facilitate pipetting. X-ray
films were taken at 30 min, 2 h and 6 hr to determine the
position of the beads in the GI tract.The level of
Eudragit coating that would give enteric protection of the
beads in the stomach was observed by noting which bead
stayed in the stomach and which did not.Figure 1.5 Each subject is orally intubated with a specific
formulation using a micro-pipette.The subject is then
put into the restrained container (squeeze bottle)
situated in the background before the x-ray is taken.23
Determination of the size of pyloric sphincter
The pyloric sphincter was unfolded longitudinally by a
surgical scissor (figure 1.6).The width, w, (perimeter of
the sphincter) was then determined using a
photomicroscope1°.The diameter of the sphincter was
calculated using the following formula:
Diameter = Perimeter / 3.1415
A total of 22 fish were examined in this part of the
study.
Optimum bead size for oral vaccine formulation
Four sizes of non-pareil sugar seeds (from 14 to 30
mesh or 0.73 mm to 1.69 mm in diameter) and two levels of
enteric coatings (10% and 15%) were used.Fish were divided
into 8 groups and fasted for 48 hours before each was fed
with a particular formulation of beads of a specified bead
diameter (0.74, 0.88, 0.98, 1.40, 0.73, 0.86, 1.04 and 1.69
mm)(table 1.4).There were 2 to 4 fish in each group.
During the experiment each fish was intubated with similar
weight (212-236 mg) of formulated beads (figures 1.7 and
1.8) using the same technique to administer the beads as
described above.The fish was then dissected after 2.5
hours and the number of beads in the stomach was counted.Figure 1.6 The pyloric sphincter is slit open longitudinally by a
pair of surgical scissors and the size (perimeter) of
the sphincter is examined under a microscope.Table 1.4Amount of Eudragit L-30D Coated Sugar Beads
Orally Intubated into Each Fish.
Level of Mesh Diameters Massa No. of beadsa
enteric coatingsize
(w/w %) (mm) (mg)
10 14-16 1.40+ 0.18 211.7+ 4.2 147 + 3
10 18-20 0.98+ 0.06 228.3+ 5.5 325 + 6
10 20-25 0.88+ 0.08 233.0+ 5.4 512 + 12
10 25-30 0.74+ 0.05 235.7+ 4.2 775 + 14
15 14-16 1.69+ 0.20 223.0+ 3.3 149 + 2
15 18-20 1.04+ 0.08 226.7+ 3.7 316 + 5
15 20-25 0.86+ 0.05 223.3+ 6.8 497 + 15
15 25-30 0.73+ 0.04 236.0+ 3.6 781 + 12
aaverage + standard error250
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The mass of 10 or 15% (w/w) EudragitL-30D coated non-
pareil sugar beads (with sizes 14-16, 18-20,20-25 and
25-30 meshes) that are orallyintubated to a fish to
determine a suitable size of sugar beads asvaccine
carriers.800 -'
700 -'
600-'
500-'
400 -'
300-'
200 -'
100-7
0
Figure 1.8
14-16 M 18-20 M 20-25 M 25-30 M
Mesh Size
10% coat 15% coat
The number of 10 or 15% (w/w) Eudragit L-30D coated non-
pareil sugar beads (with sizes 14-16, 18-20, 20-25 and
25-30 meshes) that are orally intubated to a fish to
determine a suitable size of sugar beads as vaccine
carriers.28
RESULTS AND DISCUSSIONS
Identification of lymphoid aggregates in the GI tract
Because lymphoid tissues are responsible for immune
response, they are the sites to be targeted forthe delivery
of oral vaccines.Lymphoid tissues were found to be diffuse
throughout the length of the gastrointestinal tract of Coho
salmon (figures 1.9 to I.11) and lymphocytes were scattered
throughout the esophagus, stomach, pyloric caeca and
intestine.This agrees with previous findings in carp (9).
The presence of any organized lymphoid aggregates along
the gastrointestinal tract of Coho salmon was not observed.
Therefore, it may not be necessary to develop a formulation
that will deliver the vaccine to a specific area of the
intestinal tract, but to only protect the vaccine from
gastric fluids.Uptake ability of antigen by lymphocytes in
different areas of the intestinal tract may be the focus of
research in the future.If lymphocytes in a particular area
have significantly higher antigen uptake capabilities,it
might be advantageous to focus the vaccine delivery to the
lymphocytes in this area.
Determination of the pH along the GI tract
The pH's of different segments of the gastrointestinal
tract were measured (figure 1.12).Although stomach pH has
a lot of variations (3.7 s.e. = 1.2),most observations were
under pH 4.It is very likely that protein antigens will be29
Esophagus(1 cm = 400 um)
Stomach(1 cm = 100 um)
Figure 1.9 Distribution of lymphoid tissues in the
esophagus and stomach of Coho salmon.No
organized lymphoid tissues are found.Pyloric Caeca(1 cm = 100 um)
Figure 1.10
30
Distribution of lymphoid tissues in the
pyloric caeca of Coho salmon.No organized
lymphoid tissues are found.31
Middle intestine(1 cm = 100 um)
Distal intestine(1 cm = 100 um)
Figure 1.11 Distribution of lymphoid tissues in the
middle and distal intestine of Coho salmon.
No organized lymphoid tissues are found.8
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Figure 1.12
Stomach P. Caeca U. Int.
GI Tract
L. Int.
The pH of different segments of the CohoSalmon
gastrointestinal tract.The pH ranges from acidic in
the stomach (pH 3.7) to nearly neutralin the pyloric
caeca (pH 6.9).33
destroyed/denatured in this acidic medium.The pH's of the
pyloric caeca, upper and lower portions of the intestines
are very similar and all have a pH value closeto 7.
The relative lengths of (a) esophagus-stomach (3.6 +
0.3 cm),(b) pyloric caeca (3.1 + 0.4 cm) and (c) intestine
(8.5 + 0.7 cm) to the total lengths (19.2 + 1.0 cm) of fish
are shown in figure 1.13.The variations are small (less
than 3.4%) from fish to fish.The relationship between the
weight and total length of a fish is also noted in figure
1.14.Fish weight and fish lengths are highly related(r2
equal to 0.869).
X-ray radiography on GI transit times
There are a number of theories on the gastric emptying
rate of fish and two of the most popular theories are the
exponential model and the square root model (35).Both of
them are valid only under certain conditions.
Figures 1.15 and 1.16 show the x-ray radiographic
pictures after intubation of 1 ml of barium sulfate
suspension.By 2 hours, some of the barium sulfate
suspension has emptied into the pyloric caeca.The barium
sulfate suspension took 6 to 8 hours before it reached the
intestine and had totally emptied from the pyloric caeca.
X-ray film exposure of the barium sulfate and BSA enteric
coated sugar beads was performed at 30 minutes, 2 hours and
6 hours after intubation.80-7
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Relative gut length in different parts of the GI tract
to the total length of a fish.The variations are
smaller than 3.5% from one fish to another in each
segment.Total length of fish is 19.2 + 1.0 cm.90
85
80
75
70
65
60
55
50
45
40
17.5 18 18.5 19 19.5 20 20.5
Total Length of Fish (cm)
I
Figure 1.14
21 21.5
The weight of fishg, plotted versus the total length
of the fish, cm (r' = 0.869).Figure 1.15
15 min 2 h
X-ray radiographic exposure pictures of 1 ml of barium
sulfate (72% w/v) suspension in a Coho salmon at 15 min
and 2 h after oral intubation.The barium sulfate
suspension started to enter into the pyloric caeca from
the stomach 2 hours after intubation.5 h
Figure 1.16
6 h 8 h
X-ray radiographic exposure pictures of 1 ml of barium
sulfate (72% w/v) suspension in a Coho salmon at 5,6
and 8 h after oral intubation.The barium sulfate
suspension started to empty from the intestine 6 hours
after intubation.38
Determination of Eudragit L-30D thickness for enteric
protection against fish stomach acid
Non-pareil sugar seeds of 18-20 mesh (diameter 1.00 +
0.06 mm) loaded with barium sulfate and BSA were coated with
various thickness of Eudragit L-30D and orally intubated
into Coho salmon. Comparing figures 1.1 and 1.2 with figures
1.3 and 1.4, the barium sulfate loaded 18-20 mesh beads
(diameters 1.08 mm to 1.16 mm and average mass 1.1 mg to
1.21 mg) are significantly larger and heavier than the
unloaded 18-20 mesh beads (diameter 1.00 + 0.06 mm and mass
0.62 mg).
Figures 1.17-1.20 are x-ray exposures of fish after
sugar beads having different levels of enteric coating are
orally intubated. Non-enteric coated (0% w/w Eudragit L-30D)
beads start to dissolve readily in the stomach and pass
readily to the pyloric caeca and to the intestine within 2
and 6 hours, respectively.As the level of enteric coating
increases to 5% or 10% (w/w), a larger number of beads stay
intact in the stomach and a longer time (> 2 hours) is
needed for the beads to dissolve and pass through the
stomach.When the Eudragit L-30D level reaches 15% (w/w),
the enteric coating prevents dissolution of the formulated
beads in the stomach.Also in figure 1.20, an obvious
physical barrier is seen in the x-ray film.This is a
pyloric sphincter and appears to serve the same role as the
human pyloric sphincter to prevent large particles or
undigested food from entering the next part of the30 min
Figure 1.17
2 h 7 h
X-ray radiographic exposure pictures of 40% (w/w) barium
sulfate and 5% (w/w) BSA loaded non-enteric coated non-
pareil sugar beads (1.08 + 0.05 mm in diameter) in fish
at 30 minutes, 2 hours and 7 hours after oral
intubation.30 min
Figure 1.18
2 h 7 h
X-ray radiographic exposure pictures of 40% (w/w) barium
sulfate and 5% (w/w) BSA loaded enteric-coated (5% w/w
of Eudragit L-30D) non-pareil sugar beads (1.11 + 0.06
mm in diameter) in fish at 30 minutes, 2 hours and 7
hours after oral intubation.30 min
Figure 1.19
2 h 7 h
X-ray radiographic exposure pictures of 40% (w/w) barium
sulfate and 5% (w/w) BSA loaded enteric-coated (10% w/w
of Eudragit L-30D) non-pareil sugar beads (1.11 + 0.07
mm in diameter) in fish at 30 minutes, 2 hours and 7
hours after oral intubation.30 min
Figure 1.20
2 h 7 h
X-ray radiographic exposure pictures of 40% (w/w) barium
sulfate and 5% (w/w) BSA loaded enteric-coated (15% w/w
of Eudragit L-30D) non-pareil sugar beads (1.16 + 0.07
mm in diameter) in fish at 30 minutes, 2 hours and 7
hours after oral intubation.43
gastrointestinal tract, the pyloric caeca.
Determination of the size of pyloric sphincter
The average diameter of pyloric sphincter is 0.94 + 0.1
mm.This result is consistent with the previous finding
that undissolved barium sulfate beads coated with 15%
Eudragit (average diameter > 1 mm) remained in the stomach
and did not pass to the pyloric caeca.
When the size of the pyloric sphincter was plotted
against the weight of fish, a strong direct relationship is
observed (r2 = 0.854) (figure 1.21).A plot of the diameter
of pyloric sphincter against the total length of a fish was
performed.A similar direct relationship exists between the
size of the pyloric sphincter and the length of a fish (r2
of 0.731) (figure 1.22).From the r2 values, the weight of
a fish is a better predictor of the size of the pyloric
sphincter than the length of the fish.
Optimum bead size for oral vaccine formulation
Amount of beads remaining in the stomach 2.5 hours
after oral intubation were measured (figure 1.23).Results
with both 10% and 15% enteric coated beads were similar;
i.e.that the maximum diameter of sugar beads suitable to
allow passage through the pyloric sphincter is about 1 mm
(approximately 18-20 mesh).Number of coated beads
remaining in the stomach increased when the diameter of the
beads was from 18-20 mesh size, 1 mm (26.4 + 2.5% remaining)1.2
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Figure 1.21 The diameter of the pyloric sphincter, mm, plotted
versus weight of the fish, g,(r2= 0.854).
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Figure 1.22 The diameter of the pyloric sphincter,mm, plotted
versus the total length of the fish, cm (r2 = 0.731).
21.5Figure 1.23
25-30 M 20-25 M 18-20 M
Mesh Size of Sugar Beads
14-16 M
15% coat 10% coat
The amount of Eudragit L-30D coated non-pareil sugar
left in the stomach of fish measured 2.5 hours after
oral intubation.The diameters of each of these 8
formulations are from left to right:0.73, 0.74, 0.86,
0.88, 1.04, 0.98, 1.69, 1.40 mm. The Eudragit coatings
are either 10% or 15%.47
to 14-16 mesh size, 1.4 mm (65.3 + 3.4% remaining).This is
also consistent with the results on the size of pyloric
sphincter, which has an average value of 0.94 mm.
The 10% enteric coated beads pass to the pyloric caeca
faster than the 15% enteric coated beads.It is possible
that some of the 10% enteric coated beads start to dissolve
in stomach and pass through to the pyloric caeca, as
visualized by previous x-ray pictures.All of the four
different size beads show the same trend.48
CONCLUSIONS
No aggregated lymphoid tissue exists along the Coho
salmon (Oncoryhnchus kisutch) gastrointestinal tract.It
may not be necessary to target the delivery of the vaccine
to a specific site along the GI tract except to bypass the
stomach, which has a low pH and could destroy labile
antigenic protein portions of the vaccine.
The pH of the stomach is low 3.7 + 1.2 compared to the
pH of the pyloric caeca and intestine, pH 7.0.It is very
likely that protein antigens can be denatured in this low pH
environment within 2 hours.
X-ray radiography studies showed that it takes about 2
hours before a barium sulfate suspension enters the pyloric
caeca from the stomach, and 6 to 8 hours to reach the
intestine.A 15% (w/w) Eudragit L-30D enteric coating is
required to protect the 18-20 mesh size sugar beads from
dissolving in the stomach.
The pyloric sphincter diameter is 0.94 mm ± 0.10 mm.
Sugar beads of mesh size 14-16 (diameter 1.41 mm + 0.23 mm)
are too big to pass through the pyloric sphincter.Non-
pareil sugar seeds of sizes 18-20 mesh (1.00 mm + 0.06 mm)
and smaller should be used as carriers of future oral
vaccines so that the vaccine can easily pass through the
pyloric sphincter from the stomach.
The application of 15% Eudragit L-30D coating on 18-20
mesh non-pareil sugar beads can be used to formulate oral49
vaccines.The enteric coating level needs to be adjusted if
smaller sugar beads are used when smaller fish (i.e. smaller
pyloric sphincter) are being vaccinated.50
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CHAPTER II
FORMULATION AND DISSOLUTION STUDIES OF ENTERIC-COATED
VIBRIO VACCINES56
ABSTRACT
An in vitro dissolution study was performed on enteric-
coated Vibrio anguillarum (VA LS 1-74) vaccine to determine
the optimum vaccine loading level and methacrylic acrylic
acid copolymer (Eudragit L-30D) coating thickness for
enteric protection and rapid vaccine release.Sugar beads
of size 18-20 mesh (diameter 1.00 mm + 0.06 mm) were chosen
to be the vaccine carriers.The pH at which Eudragit L-30D
coating starts to dissolve was found to be pH 5.5.When the
Eudragit coating level was 15% (w/w of final product), less
than 20% of vaccine was released in a pH 1.5 simulated
gastric fluid after 9 hours.In simulated intestinal fluid
15% Eudragit coating resulted in more than 50% vaccine
release at pH 7.2 at 75 minutes.A 10% VA LS 1-74 loading
gave the fastest release rate in simulated intestinal fluid
(pH 7.2) with 50% of the vaccine being released in 98.7 + 5
minutes.A 15% (w/w) Eudragit L-30D coating was enough to
provide protection against dissolution in simulated gastric
fluid (pH 4.5).Extended acid pretreatment time of 6 hours
delayed 50% vaccine release in intestinal fluid by 20
minutes compared to 2 hour pretreatment in simulated gastric
acid.57
INTRODUCTION
Vibriosis is a bacterial disease of salt-water and
migratory fish.Recent data indicate that annual losses due
to the disease exceed 11 million pounds in Japan alone (1)
and in severe cases there may be up to 40% mortality.Oral
vaccination was the first mass vaccination method in fish
(2).Its advantages over other methods of vaccination
include no stressful handling and no interference with
routine husbandry practice.However, most trials of oral
vaccination have resulted in low efficacy compared to
injection or immersion (3,4).
Simple (direct) immersion or dipping method was
extensively studied and found to be very successful (1).
Commercial vaccines currently available as well as results
of some previous research provide some insight on how to
formulate an oral Vibrio vaccine.
In 1980, Kusuda et al. studied the efficacy of 5
different concentrations of vaccine for bath-immunization
against vibriosis in cultured ayu (5).The final
percentages of survival in vaccinated groups 10 days after
challenge were 90%, 89%, 85%, 75% and 65% in 0.5%, 0.3%,
stock, 0.1% and 0.05% vaccine concentrations (diluted in
water), respectively.The survival ratio in unvaccinated
control was 45%.From observations on feeding activities of
vaccinated fish, immunization in stock vaccine resulted in a
more stressful environment for fish than in diluted vaccines.58
During 1981 and 1982, experiments were performed by
Anders with the aim of bath-immunizing juvenile rainbow
trout (Salmo ciairdneri) weighing under or near 1.2 g in fish
farming conditions (6).Three methods were tested.The
first preparation consisted of a vaccine whose antigens had
been liberated with trypsin.It was added to the water in
which trout were being held for 2 hours.The second vaccine
was mixed with bentonite and the pH adjusted to 3.The
trout were immersed in the vaccine for 30 seconds.The
third method was analogous to the second, but the antigen
had first been released with trypsin.No promising results
were reported.
Horne et al.(7) investigated direct immersion in 1982.
While intraperitoneal (i.p.) injections of formalized strain
of Vibrio anguillarum gave nearly complete protection,
direct immersion in the vaccine only offered 47% protection.
The authors concluded that while i.p. was not a realistic
commercial practice for fry and small fish, direct immersion
could confer worthwhile protection against natural infection
in a farmed population.Vaccination early in the season and
repeated annually was recommended.
In 1982, Johnson et al.(8) measured the duration of
immunity in salmonids vaccinated by direct immersion.The
level of protective immunity was determined using commercial
V. anguillarum (two serotypes) and Y. ruckeri (Hagerman
strain) bacterin.The duration of protective immunity
varied with the bacterin concentration, size and species of59
fish, but the duration between the two bacterins was
comparable.In fish under 1 g, duration of protective
immunity was longest when the most concentrated bacterin was
used.Generally, immunity lasted longer in larger fish.
Immunity lasted for about 120 days in 1-g fish, about 180
days in 2-g fish, but about a year or longer in 4-g or
larger fish.Coho salmon (Oncorhynchus kisutch) and sockeye
salmon (0. nerka) retained immunity for a longer time and
pink salmon (O. gorbuscha) the shortest time.Chinook
salmon (O. tshawytscha) and rainbow trout (Salmo gairdneri)
were intermediate.
Onset of immunity in salmonid fry was also determined
by Johnson et el in 1982 (9).Level of protective immunity
was measured by survival rates after bath challenge with
virulent bacteria.Immersion time for effective vaccination
was obtained within 5 seconds and protective immunity was
demonstrated within 5 days at 18°C and within 10 days at
10°C.Minimum size of salmonid fry at which maximum
protective immunity occurred was between 0 g (birth) and 5g
or an age between 1 and 2 years.Immunity appeared to be a
function of size and not age.In fish under 1 year-old, the
level of protective immunity could be increased by using a
more concentrated bacterin.
In 1984 Tatner and Horne (10) detected a period of
unresponsiveness in the very earliest groups of fry during
direct immersion.Using a radiolabelled vaccine
preparation, this was found to be due to a complete lack of60
antigen uptake at these stages.Once the fry started to
respond, they responded well and at relatively low water
temperatures.
Tatner and Horne (11) also studied factors influencing
the uptake of a 14C-labelled Vibrio anguillarum vaccine in
direct immersion experiments with rainbow trout (Salmo
gairdneri) in 1983.Immersion times of longer than 10
seconds did not increase vaccine uptake.A pre-immersion
dip in a hyperosmotic solution had no effect on uptake,even
at lower vaccine bath concentrations.It appeared that the
head of the fish was implicated in vaccine uptake.Vaccine
uptake decreased at lower temperatures, whereas the use of
an adjuvanted vaccine and a soluble vaccine preparation led
to increased antigen uptake.Larger fish took up more
vaccine.
Another successful immersion vaccination was reported
in 1984 by Kawano et al.(12)Excellent protection against
vibriosis was provided to ayu, Plecoglossus altivelis by
immersion with 5.32% NaC1 solution containing either 0.94
(wet) g/1 or 9.4 (wet) g/1 of lyophilized cells of Vibrio
anguillarum.The duration of protective immunity in the
fish was at least 113 days.However, the serum from fish
which had been vaccinated by either the immersion or oral
administration did not show detectable levels of
agglutinating antibodies against Vibrio anguillarum.
Similar results were obtained by Aoki et al.(13) using
a vaccine solution of a formalin-killed culture of Vibrio61
anguillarum. A high level of protection against artificial
challenge was achieved.The immunized fish were protected
against vibriosis when challenged 1 month after immersion.
Tatner in 1987 (14) used a radiolabel to quantitate the
relationship between vaccine dilution, length of immersion
time and antigen uptake in direct immersion experiments with
rainbow trout, Salmo gairdneri.Provided the antigen
concentration was not limiting, lengthening the immersion
time did not result in greater uptake.However, when the
antigen concentration was low, proportionally greater
periods of time were needed for antigen uptake tooccur. The
variable exerting the largest effect on uptake, however,was
fish size, with larger fish sequestering more antigen.A
constant proportion of the total antigen uptake was found in
the gut.
Increased understanding of the immune system leads one
to expect local and mucosal response to play a major role
during thevaccination process, partly because of the
enormous surface areas of the skin, gills and especially the
intestine during oral vaccination (15).
In 1988 Fujina and Nagai (16) investigated the
ingestion and transport of bovine serum albumin (BSA) into
the serum of chum salmon (Oncorhynchus keta) from the
mucosal epithelial cells in the intestine.20% BSA solution
was administered into the intestine from the anus with a
teflon tube.Results of radial immunodiffusion revealed
that 5.1 to 96.1 micrograms of BSA were detectable in 1.0 ml62
of the fish serum.This suggests the possibility of
immunization of fish by the oral route.
McLean et al.(17) confirmed that the fish gut is able
to absorb orally administered, intact proteins.In an
attempt to ascertain whether the salmonid GI tract is able
to absorb and subsequently transfer such macromolecules to
the bloodstream and tissues, the authors orally intubated
yearling chinook salmon with vitellogenin.Plasma and
tissue accumulation of a lipo-glyco-phospho-protein (MW >
600,000 daltons) were followed over 6 hours.Vitellogenin
can be considered as a model antigen in oral vaccination.
Potential problems exist in formulating oral vaccines.
First of all, antigens must be maintained intact during the
manufacturing process.A method must be developed to allow
incorporation of bacterial antigens into feed without
destroying the antigenicity (1).Excessive temperatures and
harsh processes can often denature the antigens and render
the vaccine ineffective.Palatability can also be a
problem.A palatable vaccine can ensure immunization of
every fish in the field.
Another problem which exists with oral vaccines resides
in the location of the immune areas of the fish gut.It
appears that the immune areas are located in the lower
intestine (18,19,20).To reach the second gut, and thus to
induce an immune response, the antigens must first pass
through the stomach of the fish.It is possible that the
high acid concentrations in the stomach may destroy the63
antigens.This hypothesis is supported by the increased
efficacy of Vibrio vaccines administered by anal intubation
rather than orally (21).So far, microencapsulated and
slow-release oral vibrio vaccines have been developed in
1989 but their efficacies were reported to be even lower
than unprotected vaccine (22).
Recently oral vaccines are actively being developed for
a number of human and animal diseases such as cholera (23-
26), typhoid fever (27-30), rabies (31), vulvovaginal
candidiasis (32), hepatitis B (33), influenza (34) andmany
others (chlamydiasis, colibacillosis, Yersinia
enterocolitica, feline leukemia).
Cholera is caused by the human pathogen Vibrio cholerae
01 and share many common characteristics with Vibrio
anguillarum, a fish pathogen.Vibrio cholerae adheres to
mucosal enterocytes and produces an enterotoxin which has a
molecular weight of 83,000 (35). This enterotoxin consists
of two distinct types of subunits, A and B. Subunit A (MW
28,000) is noncovalently attached to five B subunits (each
of 11,000 MW).Purified B subunit of cholera toxin retains
membrane-binding capacity and protective immunogenicity and
yet has no toxic activity as tested in animals (36).
Several approaches to the development of a safe and
effective vaccine against Vibrio cholerae include (a)
purified enterotoxin B subunit plus killed whole cells of
Vibrio cholerae,(b) attenuated live Vibrio cholerae strains
and (c) cloned Vibrio cholerae antigens in a Salmonella64
carrier strain (37).
A major uncertainty about the oral vaccine is whether
it requires protection from gastric acid to retain full
immunogenicity in the small intestine. During a ganglioside
ELISA, the B subunits exhibited almost no activity below a
pH level of 3(38,39).This lack of activity was explained
to be the the result of reversible dissociation of the B
subunits from pentameric to monomeric form below a pH level
of 4.Diminished IgG antibody responses to B subunits were
also observed when B subunits were administered without
antacids.The simplicity and equivalent immunogenicity of
mixing vaccine with antacid for simultaneous administration
were suggested (39).
In 1987, Chaicumpa et al.(40) used albino rats aged 7
to 9 weeks as an animal model to study the immunogenicity of
Vibrio cholerae antigens.To protect the antigens from
stomach acid, 1 ml of 5% NaHCO3 was given prior to oral
immunization.
In 1988, Pierce et al.(41) used intravenous cimetidine
and NaHCO3 to neutralize the gastric acid to increase the
immunogenicity of their Vibrio cholerae 01 vaccine in
rabbits.
Beside cholera vaccine, other vaccines can also be
subject to acid degradation in the stomach and warrant
enteric protection to increase their efficacies.One of
these examples is the typhoid vaccine.
In 1983 Ty21a, a stable attenuated mutant of Salmonella65
typhi, was considered a safe and protective oral vaccine
when 3 doses of 109 cells in saline were taken after
neutralization of gastric acidity by 1 g NaHCO3 (42).To
identify a more convenient method of administering the
vaccine, 141 U.S. adults received vaccine formulated in
either one of the two ways:(a)in gelatin capsules
administered with two additional gelatin capsules containing
a total of 0.8 gm NaHCO3 or (b) in enteric coated capsules.
Rates of seroconversion of antibody were similar in all
groups. Based on these observations a large-scale field
trial of efficacy has been initiated in 90,000 school
children 6 to 20 years of age in Santiago, Chile.One third
of these subjects received one dose of enteric coated
vaccine; one-third received two doses and the remainder
received placebo.
Vaccine in enteric coated capsules was found to bea
safe and practical means for mass immunization and more
effective than a formulation consisting of gelatin capsules
containing vaccine and NaHCO3 (43).One dose of enteric
coated vaccine was not sufficiently immunogenic, but two and
three doses provided 54 to 62% protection for a period of 33
months and 18 months, respectively.
Levine at al.(44) confirmed that three doses of Ty2la
attenuated Salmonella typhi oral vaccine in enteric coated
formulation provided 67% protection for at least 3years in
a randomized, placebo-controlled field trial.Ty2la
provides the same level of protection as the heator phenol-66
inactivated whole cell parenteral vaccine but it causes less
adverse reactions.
In April 1990, this live oral vaccine (Ty21a) in the
form of enteric coated capsules was approved by the Food &
Drug Administration (FDA).One enteric coated vaccine
capsule is to be taken on alternate days for a total of four
capsules.A booster dose is recommended every four years if
exposure is continuous or repeated (45).
Enteric coated capsules have also been used in the
formulation of other vaccines that are acid-labile.A
killed influenza vaccine consisting of 98 micrograms of
Bangkok A hemagglutinin was given in enteric coated capsules
and led to significant salivary and nasal IgA antibody rises
in a 4-week period (46,47).The orally administered vaccine
was associated with no more side effects than placebo and
had less side reactions than the intramuscular route.The
intramuscular route also did not stimulate antibody
production in saliva and nasal secretions while secretory
IgA antibody produced by oral vaccination may be important
in protection against respiratory viral infections.
In 1986 Ishihara et al.(48) administered BCG vaccine
in enteric coated capsules to 27 patients of malignant
melanoma in additional to chemotherapy after surgical
treatment while another 27 patients of the same stage of
melanoma were treated with chemotherapy alone after surgery.
The BCG group showed a significantly higher survival rate
and a slightly higher disease free time.67
So far the development of Vibrio anguillarum immersion
vaccines have been discussed and some insights were given on
how formulated oral vaccines which were ineffective, may
have been degraded by the high acidic environment in the
stomach.Several ways to improve the efficacy of an oral
vaccine were (a) anal intubation of the antigen,(b) adding
NaHCO3 to the vaccine,(c) neutralizing the stomach acid by
cimetidine or NaHCO3 prior to oral immunization and (d)
forming an enteric coated capsule of the vaccine.
The last method of improving efficacy of an oral
vaccine has been chosen in this study.An enteric coated
oral Vibrio anguillarum (VA LS 1-74) vaccine was developed.
VA LS 1-74 was coated on the surface of small sugar beads
and then Eudgrait L-30D was applied on top to serve as an
enteric coating.Reported here are the dissolution studies
performed to analyze the release patterns of VA LS 1-74
vaccine developed.Methacrylic acrylic acid copolymer
(Eudragit L-30D) was chosen to be the enteric coating
material because it is extensively used in pharmaceutical
industry.The coating films are insoluble in pure water, in
buffer solutions below pH 5.0 and also in natural and
artificial gastric fluids.However, the films are soluble
in the neutral to weakly alkaline region of the digestive
tract and in buffer solutions above pH 5.5.
Specific objectives of this study include
identification of the spray coating conditions for VA LS 1-68
74 and Eudragit L-30D to avoid antigen degradation. The pH
at which Eudragit L-30D starts to dissolve was examined.
The loading level of VA LS 1-74 in the sugar beads for rapid
vaccine release and the optimum coating thickness of
Eudragit L-30D for enteric protection were identified
together with a formulation which is to be used to run an
in-vivo challenge test.Lastly, the effects of gastric acid
pretreatment on dissolution are presented.69
MATERIALS AND METHODS
Materials
Vibrio anguillarum, VA LS 1-74
A pure stock of VA LS 1-74 was obtained from a
lyophilized source stored in a -70°C freezer'.The
lyophylized bacteria were thawed and cultured on a tryptic
soy broth agar plate.During any transfer process the
purity of each colony was monitored by streaking out an agar
plate and examined under a microscope after Gram's stains
were performed.
Culture media and agar plates
Tryptic soy broth powder2, 30 grams,was dissolved in
water to make up 1 liter of culture.To prepare agar plates
1.5 grams of agar powder3 was added to every 100 ml culture
media.
Sugar beads4
Non-pareil sugar beads of 1820 mesh size with a
diameter of 1.00 + 0.06 mm and an average mass of 62 mg/100
beads were used.The sugar bead was coated with VA LS 1-74
to yield a final weight of 10% of the bead weight.
Approximately 50 beads will deliver a dose of 3 mg
lyophilized bacteria, which was chosen as the dose of the
vaccine per day for each fish.70
Enteric coating material
Eudragit L -30D5 (methacrylic acrylic acid copolymer)
was chosen to provide a colorless latex and transparent
enteric coating, which is insoluble in pure water, in buffer
solutions below pH 5.0 and also in gastric fluids.This
coating is soluble in buffer solutions above pH 5.5 and
neutral to weakly alkaline region of the digestive tract.
This product comes as a 30% dry lacquer.
Plasticizer/Lubricant
Polyethylene glycol 6000, PEG 60006, was the
plasticizer and talc7 was the lubricant.
Reagents for Lowry's protein assay
A 2% sodium tartrate, Na2C4H4O68 solution (named Al) was
made by dissolving 2.0 grams of sodium tartrate in 100 ml of
distilled water.A 1% copper sulfate, CuSO4.5H209 solution
(named A2) was prepared by dissolving 1.0 gram in 100 ml of
distilled water.A 2% sodium carbonate, NaC031° solution
(named A3) was made by dissolving 20.0 grams in 1 liter of
0.1 N Na0H11.Solution A was prepared by mixing Al, A2 and
A3 in a 1:1:100 ratio.Folin & Ciocalteu's Phenol Reagent,
2.0 Norma112, was obtained commmercially and a 1:1 dilution
in distilled water (named B) was used during theassay.
Methods
Mass culture techniques for Vibrio Anguillarum, VA LS 1-7471
The optimum growth conditions for bacteria were found
to be at 18°C in a culture room.Aseptic techniques were
observed.All culture media, containers and glassware were
autoclaved13 before and afteruse.All culture flasks
contained tryptic soy broth as the growth media, had a
cotton plug to avoid air contamination and were secured
firmly on a shaker14 to provide aeration.To start, a test
tube containing 10 ml of tryptic soy broth was inoculated
with stock VA LS 1-74 grown on an agar plate. After 24 hours
this culture was transferred to another 100 ml sterile media
in a 250 ml flask. Another 24 hours elapsed and 10 ml
portions of this culture were removed and added to 2 liter
flasks, each of which contained 1 liter tryptic soy broth.
To replenish the carbon source and neutralize the media pH,
20 ml of 20% dextrose's and 0.8 ml of 10 N NaOH16 were added
after 12 hours.The culture was then left on the shaker for
another 12 hours before it was harvested with 3 ml (0.3% of
culture volume) of formalin17.A tryptic soy broth agar
plate was streaked every time the culture was transferred
from one flask to another to assure purity or sterility.
The cells were centrifuged18 at 10,000 x g for 20 minutes
under 4°C and were rinsed three times with phosphate
buffered saline (PBS)(see Table II.I) before
lyophilization.The lyophilization process was kindly
performed by Mrs. Ilsa Kaattari (Instructor of Microbiology,
Microbiology Department, OSU).72
Table I1.1Composition of Phosphate Buffered Saline, PBS.
1.1 liter Phosphate buffered saline (PBS)
use NaC1 8.0 g
Na2HPO4.7H20 2.0 g
KH2PO4 0.2 g
KC1 0.2 g
For convenience, a 10X PBS solution was usually prepared
and diluted to one-tenth of its volume immediately before use.
a Sigma Chemical Company, St. Louis, Missouri73
Preparation of VA LS 1-74 loaded sugar beads
Lyophilized VA LS 1-74 was resuspended in 70%
methanol19 or ethano120 to producea final concentration of
5% suspension.To assure homogeneity, this suspension was
mixed in a blender21 at low speed for 15 seconds.It was
then spray coated on non-pareil sugar seeds4 of mesh size
18-20 (1.00 ± 0.06 mm) to produce a final VA LS 1-74 loading
of 10%, 15%, 20% or 25% (w/w of lyophilized VA LS 1-74/final
product) for test products.The spray-coater was an
Aerocoat Strea-1 spray coater with a modified Lab-
line/P.R.L. High Speed Fluid Bed Dryer22.A peristaltic
pump23 was used to deliver the suspension to thespray
coater at a rate of about 2.5 ml/minute with constant mixing
using a magnetic stirring bar.Temperature was set at 40°C
and nozzle pressure was maintained at 10 - 15 psi.The
vaccine loaded beads were dried in an oven at 60°C for 2
days before they were spray coated with Eudragit L-30D.
Enteric coating of VA LS 1-74 loaded sugar beads vaccines
The Aerocoat spray coater was used to apply Eudragit L-
30D on the surface of dried VA LS 1-74 loaded sugar beads.
The coating solution was Eudragit L-30D together with PEG
6000 (25% w/w of Eudragit) as a plasticizer and talc (7
parts of talc to 30 parts of Eudragit in weight) as a
lubricant (Table 11.2).Temperature was set at 35°C and
nozzle pressure maintained at 10 - 15 psi.Rate of coating
was about 2.2 to 2.5 ml/minute.Four enteric-coating levels74
Table 11.2Composition of Enteric Coating Solution.
Eudragit L-30Da (30% lacquer)
Polyethylene glycol 6000b
(25% w/w of dry Eudragit)
Talc
440 ml
33.0 g
30.8 g
(7 parts to 30 parts of dry Eudragit in weights)
H2O q.s. 979 ml
to make a 20% w/v solution
a Rohm Pharma, Weiterstadt, West Germany
bSigma Chemical Company, St. Louis, Missouri, U.S.A.75
(5%, 15%, 25% and 35% by weight of dried vaccine loaded
beads) were examined and table 11.3 is a summary of various
formulations developed.
Dissolution of enteric coated VA LS 1-74 loadedsugar beads
All formulations in this study utilized non-pareil
sugar seeds of mesh size 18-20 (1.00 + 0.06 mm).Vaccine
beads of each formulation containing 30 mg of lyophilized
bacteria (based on theoretical calculation) were placed ina
U.S.P. dissolution basket (figure II.1).This dissolution
basket was then put inside a 250 ml beaker.Unless
otherwise specified, 30 ml of U.S.P. simulated gastric fluid
without enzymes (phosphate buffered to pH 4.5) (table 11.4)
was used in the first hour of the dissolution and replaced
by 30 ml of U.S.P. simulated intestinal fluid without
enzymes (phosphate buffered to pH 7.2) starting from the
second hour of the dissolution study.The surrounding
solution was agitated with a magnetic stirring bar at about
160 + 20 rpm to ensure a uniform concentration of dissolved
VA LS 1-74.Temperature was maintained constant by a water
bath at about 18°C, which is close to the temperature (12°C)
at which fish are kept. The sampling volume was 100 ul and
the same amount of GI fluid was added to the dissolution
fluid after a sample was taken. Each sample was studied in
triplicate and analyzed by Lowry's protein assay.Standard
calibration curve for VA LS 1-74 was set up on each day for
different dissolution media.76
Table 11.3 Composition of Oral Enteric Coated Vaccines.
Formulation VA LS 1-74 Eudragit
loading (%) L-30D coating(%)
1 10 0
2 10 5
3 10 15
4 10 25
5 10 35
6 15 15
7 20 15
8 25 0
9 25 5
10 25 15
11 25 25
12 25 35Figure 11.1 During dissolution study, Vibrio anquillarum loaded and
Eudragit L-30D coated sugar bead vaccine was put in a
U.S.P. dissolution basket and the surrounding medium was
agitated by a magnetic stirring bar to enhance mixing.78
Table 11.4Composition of U.S.P. Simulated Gastric or
Intestinal Fluid without Enzymes.
a. U.S.P. simulated gastric fluid without enzymes
NaCla 2.0 g
HCla 7.0 ml
H2O q.s. 900 ml
Adjust to desired pH with 10% HC1.
b. U.S.P. simulated intestinal fluid without enzymes
KH2PO4a 6.8 g
0.2 N NaOHa 190 ml
H2O 400 ml
Adjust to desired pH with 10% HC1.
a Sigma Chemical Company, St. Louis, Missouri, U.S.A.79
Determination of the pH at which Eudragit L-30D startsto
dissolve
Vaccine beads coated with 10% VA LS 1-74 and 15%
Eudragit L-30D were dissolved in simulated GI fluids of pH's
4.5, 5.5, 6.0 and 7.2.The sampling times were 15 min., 30
min., 45 min., 1 h, 1.25 h, 1.5 h, 1.75 h,2 h, 2.5 h,3 h,
6 h and 9 h.
Preliminary study
Non-enteric coated and enteric coated (15% Eudragit L-30D)
vaccine beads containing 10% VA LS 1-74 were used in this
part of the dissolution tests, which consisted of four (i-
iv) different conditions.(i) The non-enteric coated
vaccine was dissolved in a pH 7.2 simulated intestinal
fluid.To compare,(ii) the enteric-coated vaccine was put
in the same type of intestinal fluid or (iii) pH 1.5
simulated gastric fluid.Also,(iv) the enteric-coated
vaccine was pretreated in pH 1.5 simulated gastric fluid for
1 hour before the vaccine was dissolved in pH 7.2 simulated
intestinal fluid.The sampling times were 15 min., 30 min.,
45 min., 1 h, 1.25 h, 1.5 h, 1.75 h,2 h, 2.5 h,3 h,6 h
and 9h.
Determination of the appropriate VA LS 1-74 loading level
for rapid vaccine release
Enteric-coated (15% Eudragit L-30D) vaccine beads
loaded with various levels (10%, 15%, 20% or 25%)VA LS 1-80
74 were dissolved in pH 4.5 simulated gastric fluid for the
first hour and in pH 7.2 simulated intestinal fluid
thereafter.The sampling times were 15 min., 30 min., 45
min., 1.25 h, 1.5 h, 1.75 h,2 h,3 h,4 h,6 h and 12 h.
Determination of the optimum Eudragit L-30D coating as
enteric protection
Vaccine beads loaded with either 10% or 25% VA LS 1-74
and enteric-coated with various levels of Eudragit L-30D
were dissolved in pH 4.5 simulated gastric fluid for the
first hour and in pH 7.2 simulated intestinal fluid
thereafter.The sampling times were 15 min., 30 min., 45
min., 1.25 h, 1.5 h, 1.75 h,2 h,3 h,4 h,6 h and 12 h.
Gastric acid pretreatment effect
Vaccine beads coated with 10% VA LS 1-74 and 15%
Eudragit L-30D were pretreated in simulated pH 4.5 gastric
fluid for 2,4 or 6 hours and were then dissolved in pH 7.2
simulated intestinal fluid.The sampling times were 0 min.,
15 min., 30 min., 45 min., 1 h,2 h,3 h,5 h and 11 h.
Lowry's protein assay to measure amount dissolved
To quantitate the amount of VA LS 1-74 dissolved from
our formulation, Lowry's protein assay method was used as
follows:
To each sample, 2 ml of solution A (see Materials
section) was added.After 10 minutes, 200 ul of reagent B81
(see Materials) was added.After an incubation time of 30
minutes, the absorbance was read at 500 nm.The samples
were separated from each other in such a manner that the
absorbance was read exactly at the end of the 30 minute
incubation.82
RESULTS AND DISCUSSION
Figure 11.2 is a typical calibration curve of Vibrio
anguillarum at pH 7.0 using Lowry's protein assay.From the
summary data of this standard curve (table 11.5), the
concentration of VA LS 1-74 and absorbance are highly
linearly related with a high correlation coefficient, r2 of
0.994.
Effect of pH on dissolution
To identify the exact pH at which the enteric coating
will begin to dissolve, dissolution experiments were done at
different pH's.Figure 11.3 is the calibration curve of VA
LS 1-74 at different pH's.The pH 7.2 standard curve was
performed one more time to ensure the consistency of the
results.It was observed that absorbance slightly increased
for similar concentrations of VA LS 1-74 when pH increased.
Figure 11.4 is the dissolution graph at various pH's (table
11.10).Enteric coated vaccine began to dissolve at pH's
above 5.5 and this agrees with the manufacturer's
specification for Eudragit L-30D.
Preliminary study
As a preliminary study, enteric coated (15% w/w
Eudragit L-30D) and non-enteric coated VA LS 1-74 loaded
(10% w/w) vaccine beads were dissolved in simulated gastric
(pH 1.5) and simulated intestine fluid (pH 7.2) without0.5
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0.3
0.2
0.1
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0.00.10.2
Figure 11.2
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0.91.0
Standard curve for Vibrio anguillarum LS 1-74 in pH 7.0
U.S.P. simulated GI phosphate buffer by Lowry's protein
assay, estimated using linear regression.84
Table 11.5 Typical Standard Curve Data for Vibrio Anguillarum
Concentration at pH 7.0 Estimated Using Linear
Regressiona.
Inv. Est.
Std. No.Conc. Absorbance Conc.b % Theoryc
(mg/ml) (mg/ml)
1 0.00 0.000 -0.010
2 0.20 0.115 0.232 116.2
3 0.40 0.195 0.403 100.7
4 0.60 0.280 0.584 97.4
5 0.80 0.368 0.772 96.5
6 1.00 0.485 1.022 102.2
Mean 102.6
S.D. 8.0
%C.V.d 7.8
a R2 = 0.996
bInversely estimated concentration = -0.013 + 2.133X
(Absorbance)
c % Theory = (Inversely estimated concentration/known
concentration) x 100
d% Coefficient of variation = (S.D./Mean) x 100pH R2
04.5 0.999
5.5 0.997
A6.0 0.997
7.2 0.998
0.0tilii
0.00.10.20.30.40.50.60.70.8
Figure 11.3
Concentration (mg/ml)
0.9
Standard curve for Vibrio anquillarum LS 1-74 in pH 4.5,
5.5 and 6.0 U.S.P. simulated gastric fluid by Lowry's
protein assay, estimated using linear regression.
1.086
Table 11.6Standard Curve Data for Vibrio Anguillarum
Concentration in Figures 11.4 and 11.5 at pH 4.5
Estimated Using Linear Regressiona.
Inv. Est.
Std. No.Conc. Absorbance Conc.b % Theoryc
(mg/ml) (mg/ml)
1 0.00 0.050 -0.016
2 0.20 0.121 0.199 99.6
3 0.40 0.196 0.425 106.2
4 0.60 0.254 0.601 100.1
5 0.80 0.325 0.818 102.3
6 1.00 0.376 0.973 97.3
Mean 101.1
S.D. 3.4
%C.V.d 3.3
a R2 = 0.997
bInversely estimated concentration = -0.169 + 3.035X
(Absorbance)
c % Theory= (Inversely estimated concentration/known
concentration) x 100
d% -6 Coefficient of variation = (S.D./Mean) x 10087
Table 11.7Standard Curve Data for Vibrio Anguillarum
Concentration in Figures 11.4 and 11.5 at pH 5.5
Estimated Using Linear Regressiona.
Std. No.Conc.
(mg/ml)
Absorbance
Inv. Est.
Conc.b
(mg/ml)
% Theoryc
1 0.00 0.055 -0.027
2 0.20 0.138 0.228 113.9
3 0.40 0.195 0.402 100.5
4 0.60 0.063 0.613 102.1
5 0.80 0.324 0.800 100.0
6 1.00 0.384 0.984 98.4
Mean 103.0
S.D. 6.3
%C.V.d 6.1
a R2 0.997
b Inversely estimated concentration= -0.197 + 2.991X
(Absorbance)
C % Theory= (Inversely estimated concentration/known
concentration) x 100
d % Coefficient of variation= (S.D./Mean) x 10088
Table 11.8Standard Curve Data for Vibrio Anguillarum
Concentration in Figures 11.4 and 11.5 at pH 6.0
Estimated Using Linear Regressiona.
Std. No.Conc. Absorbance
(mg/ml)
Inv. Est.
Conc.b
(mg/ml)
% Theoryc
1 0.00 0.056 -0.015
2 0.20 0.127 0.196 98.2
3 0.60 0.202 0.418 104.5
4 0.60 0.269 0.615 102.4
5 0.80 0.338 0.819 102.4
6 1.00 0.388 0.967 96.7
Mean 100.8
S.D. 3.3
%C.V.d
a R2 0.997
bInversely estimated concentration=-0.180
3.2
+ 2.953X
(Absorbance)
c % Theory = (Inversely estimated concentration/known
concentration) x 100
d% Coefficient of variation = (S.D./Mean) x 10089
Table 11.9Standard Curve Data for Vibrio Anguillarum
Concentration in Figures 11.4 and 11.5 at pH 7.2
Estimated Using Linear Regressiona.
Inv. Est.
Std. No.Conc. Absorbance Conc.b % Theoryc
(mg/ml) (mg/ml)
1 0.00 0.061 -0.025
2 0.20 0.141 0.207 103.7
3 0.40 0.214 0.420 104.9
4 0.60 0.284 0.623 103.8
5 0.80 0.346 0.803 100.4
6 1.00 0.404 0.972 97.2
Mean 102.0
S.D. 3.2
%C.V.d 3.1
a R2 = 0.999
bInversely estimated concentration = -0.204 + 2.939X
(Absorbance)
c % Theory= (Inversely estimated concentration/known
concentration) x 100
d% Coefficient of variation - (S.D./Mean) x 100110
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Table 11.10 In Vitro Dissolution of VA LS 1-74 from 10% Vibrio
Loaded and 15% Eudragit L-30D Coated Vaccine Beads
at Different pH's.
Dissolution Mean Percent of Releaseda + SDb
Time 1c 2d 3e f
15 min 0.0± 0.0 0.0± 0.0 0.6± 0.2 11.9+ 1.8
30 min 0.0± 0.0 0.0± 0.0 4.8± 0.3 31.3+10.8
45 min 0.0± 0.0 0.0± 0.0 9.8± 0.928.2+ 2.7
1 hr 0.0± 0.0 4.1± 1.515.9± 1.3 31.7+ 6.2
1.25 hr 0.9± 1.3 2.4± 0.824.0± 4.157.4+ 3.3
1.5 hr 0.9± 0.5 3.3± 0.638.3± 6.673.0+ 9.0
1.75 hr 0.9± 0.8 4.4± 0.829.7± 2.786.6+ 4.1
2 hr 0.9± 0.3 5.4± 1.250.2± 8.984.5+ 6.8
2.5 hr 0.9± 0.3 8.9± 3.557.0±14.884.5+ 6.8
3 hr 2.4± 2.0 8.9± 0.459.9± 5.392.1+ 2.3
6 hr 6.2± 2.7 11.6± 0.889.4± 3.996.7+ 2.4
9 hr 3.9± 0.5 11.3± 0.6100.0± 0.0100.0+17.7
aMean value of three replicates
b Standard deviation values for eachmean percent
b pH 4.5
dpH 5.5
e pH 6.0
fpH 7.2cn
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enzymes.Figure 11.6 depicts the calibration curves of VA
LS 1-74 in simulated gastric (pH 1.5) and intestinal (pH
7.2), fluids, respectively while tables 11.11 to 11.12
summarize the data of these standard curves.Again, linear
relationships were observed with correlation coefficients r2
of 0.994 and 0.996.
Enteric coated vaccines did not dissolve in the low pH
of 1.5 simulated gastric fluid after 9 hours (figure 11.7)
while the non-enteric coated vaccines were readily released
in simulated intestinal fluid (pH=7.2).Eudragit L-30D
coating slowed the release of VA LS 1-74 at the beginning
but more than 50% was dissolved in about 1 hour (less than
70 minutes) in both cases (figure 11.8).Pretreatment of
enteric coated vaccines in gastric fluid for 1 hour seemed
to speed up the dissolution rate slightly probably due to
water penetration.50% of VA LS 1-74 was dissolved in about
40 minutes after one hour acid pretreatment.
This study confirmed that Eudragit L-30D serves as a
protective coating against stomach acid and the vaccine
releases from the beads readily at the intestinal pH.
Because the enteric coated VA LS 1-74 loaded beads would be
incorporated into the Oregon Test Diet (OTD), which usually
has a higher pH than stomach fluid, a certain proportion of
the vaccine beads might be expected to dissolve in OTD.To
determine the dissolution conditions for later studies, pH
paper was used to determine the pH of OTD.The pH of
intestine of Coho salmon (Oncorhynchus kisutch) was0.5-
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Concentration (mg/m1)
Standard curve for Vibrio anguillarum LS 1-74 in pH 1.5
and 7.2 U.S.P. simulated GI phosphate buffers by Lowry's
protein assay, estimated using linear regression.95
Table II.11 Typical Standard Curve Data for Vibrio Anguillarum
Concentration at pH 1.5 Estimated Using Linear
Regressiona.
Inv. Est.
Std. No.Conc. Absorbance Conc.b % Theoryc
(mg/ml) (mg/ml)
1 0.00 0.074 0.021
2 0.20 0.128 0.203 101.3
3 0.40 0.175 0.360 90.1
4 0.60 0.256 0.632 105.3
5 0.80 0.295 0.763 95.4
6 1.00 0.372 1.021 102.1
Mean 98.8
S.D. 6.1
%C.V.d 6.2
a R2 0.993
bInversely estimated concentration = -0.227 + 3.355X
(Absorbance)
c % Theory = (Inversely estimated concentration/known
concentration) x 100
d % Coefficient of variation = (S.D./Mean) x 10096
Table 11.12 Typical Standard Curve Data for Vibrio Anguillarum
Concentration at pH 7.2 Estimated Using Linear
Regressiona.
Inv. Est.
Std. No.Conc. Absorbance Conc.b % Theoryc
(mg/ml) (mg/ml)
1 0.00 0.058 -0.030
2 0.20 0.141 0.210 105.2
3 0.40 0.217 0.431 107.7
4 0.60 0.281 0.617 102.8
5 0.80 0.344 0.799 99.9
6 1.00 0.404 0.973 97.3
Mean 102.6
S.D. 4.1
%C.V.d 4.0
a R2 = 0.996
bInversely estimated concentration = -0.199 + 2.901X
(Absorbance)
c % Theory= (Inversely estimated concentration/known
concentration) x 100
d% Coefficient of variation = (S.D./Mean) x 100140 .-..--
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Table 11.13 In Vitro Dissolution of VA LS 1-74 from 10% Vibrio
Loaded and 15% Eudragit L-30D Coated Vaccine
Beads.
Dissolution
Time
MeanPercent of Releaseda+ SDb
1c 2d 3e 4f
15 min38.3± 6.2 11.9± 1.8 8.9± 5.015.7± 7.1
30 min37.5± 7.4 31.5±10.815.7± 4.317.1± 2.4
45 min61.5±11.328.2± 2.7 9.4± 0.811.0± 0.6
1 hr 95.1±25.031.7± 6.2 8.2± 5.510.4± 7.6
1.25 hr98.5±25.057.4± 3.3 9.7± 1.5 1.4± 2.1
1.5 hr109.0±19.7 73.0± 9.031.3±10.1 6.8± 2.5
1.75 hr97.5± 7.186.6± 4.145.7± 4.619.5±16.0
2 hr 95.2±14.284.5± 6.870.6±11.517.5± 6.0
2.5 hr100.0± 5.471.2± 5.386.6±11.1 15.2± 4.1
3 hr 112.0± 8.892.1± 2.3 84.4± 1.119.4± 5.7
6 hr 100.0± 2.1 96.7± 2.490.0± 0.1 7.2± 2.4
9 hr 100.0±19.6100.0±17.7100.0± 0.619.5±12.3
aMean value of three replicates
b Standard deviation values for eachmean percent
c Non-enteric coated VA LS 1-74 loaded vaccine beads at pH 1.5
dEnteric coated VA LS 1-74 loaded vaccine beads at pH 7.2
e Enteric coated and pretreated in the gastric fluid for the
first hour
fEnteric coated VA LS 1-74 loaded vaccine beads at pH 1.5N 100
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determined in parts of this thesis.The pH's were found to
be 3.5-4.5 and 7.2, respectively.Unless otherwise
specified, pH 4.5 simulated gastric fluid would be used
during the first hour in later dissolution experiments.
After the first hour, pH 7.2 simulated intestinal fluid
would be used.
Figure 11.9 is a typical standard curve for VA LS 1-74
at pH 4.5 or 7.2.Both regression lines show a linear
relationship between absorbance and vaccine concentration
with an r2 of 0.999.
VA LS 1-74 loading effect on dissolution
With the same Eudragit L-30D coating level (15%) and
pretreatment time (1 hour) in simulated gastric fluid, 10%
loading of VA LS 1-74 gave the fastest release in simulated
intestinal fluid (figures II.10).It took 98.7 + 5 minutes
for 50% dissolution (figure II.11).15% loading had the
slowest dissolution rate.Size of the vaccine bead seemed
to play an important role in determining the release rate.
Because VA LS 1-74 is loaded on sugar beads that are of the
same size (mesh 18-20), an increase in loading will increase
the size of the final product beads.Therefore, high VA LS
1-74 loading may have a slower dissolution rate.On the
other hand, high VA LS 1-74 loading could result in a larger
concentration gradient around the vaccine beads increasing
the dissolution rate and offset the size effect.This may
explain why 20% and 25% loaded beads had shorter times for0.5.1-
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Concentration (mg/m1)
Standard curve for Vibrio anguillarum LS 1-74 in pH 4.5
and 7.2 U.S.P. simulated GI phosphate buffers by Lowry's
protein assay, estimated using linear regression.102
Table 11.14 Standard Curve Data for Vibrio Anguillarum
Concentration in Figures 11.10 to 11.17 at pH 4.5
Estimated Using Linear Regressiona.
Inv. Est.
Std. No.Conc. Absorbance Conc.b % Theoryc
(mg/ml) (mg/ml)
1 0.00 0.060 0.005
2 0.20 0.133 0.214 107.0
3 0.40 0.198 0.408 101.9
4 0.60 0.254 0.576 95.9
5 0.80 0.327 0.796 99.5
6 1.00 0.399 1.012 101.2
Mean 101.1
S.D. 4.0
%C.V.d 4.0
a R2 = 0.999
bInversely estimated concentration = -0.184 + 2.996X
(Absorbance)
c % Theory= (Inversely estimated concentration/known
concentration) x 100
d% Coefficient of variation = (S.D./Mean) x 100103
Table 11.15 Standard Curve Data for Vibrio Anguillarum
Concentration in Figures 11.10 to 11.17 at pH 7.2
Estimated Using Linear Regressiona.
Inv. Est.
Std. No.Conc. Absorbance Conc.b % Theoryc
(mg/ml) (mg/ml)
1 0.00 0.055 0.013
2 0.20 0.110 0.178 89.0
3 0.40 0.187 0.409 102.2
4 0.60 0.252 0.604 100.6
5 0.80 0.315 0.793 99.1
6 1.00 0.386 1.004 100.4
Mean 98.3
S.D. 5.3
%C.V.d 5.4
a R2 = 0.999
b Inversely estimated concentration= -0.152 + 2.998X
(Absorbance)
c % Theory= (Inversely estimated concentration/known
concentration) x 100
d % Coefficient of variation= (S.D./Mean) x 100110T
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Table 11.16 In Vitro Dissolution of VA LS 1-74 from Various
Levels of Vibrio Loaded and 15% Eudragit L-30D
Coated Vaccine Beads.
Dissolution Mean Percent of Releaseda + SDb
Time lc 2d 3e 4f
15 min
30 min
45 min
1.25 hr
1.5 hr
1.75 hr
2 hr
3 hr
4 hr
6 hr
12 hr
0.0± 0.0 1.6+ 0.5 0.0± 0.0 0.0± 0.0
1.2± 2.7 3.1± 1.0 3.8± 0.4 0.0± 0.0
3.2± 3.3 3.1± 2.4 0.2± 2.5 0.0± 0.0
17.7± 4.1 9.5± 0.520.4± 4.2 7.6± 0.5
41.6± 9.7 17.0± 1.225.9± 4.2 30.4± 1.1
56.1± 8.833.2± 3.953.5± 8.943.5± 1.6
60.1± 5.442.5± 3.867.6± 8.452.6± 2.7
78.2± 5.3 50.1± 8.575.9± 6.067.7± 5.1
99.3±11.7 56.3±11.479.4± 6.684.2± 6.8
102.3± 1.175.3± 4.486.6± 9.698.8±11.4
100.0± 0.0100.0± 0.0100.0± 0.0100.0± 0.0
a Mean value of three replicates
b Standard deviation values for eachmean percent
10%VA LS1-74loading
d15%VA LS1-74loading
e20%VA LS1-74loading
f25%VA LS1-74loading(r)
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50% release.
Effect of enteric coating levels on dissolution
Loading of VA LS 1-74 was kept constant (either 10% or
25%) and the levels of Eudragit L-30D coatings were varied
from 5% to 35%.5% Eudragit L-30D coating did not provide
enough protection against dissolution in gastric fluid and
more than 10% of the vaccine was released during the first
hour in pH 4.5 simulated gastric fluid (figures 11.12 and
11.13).A 15% of Eudragit coating gave sufficient
protection against gastric fluid and the dissolution rate in
intestinal fluid was rapid, releasing 75% during the first
hour in simulated intestinal fluid.Times for 50% release
were longer for 25% or 35% Eudragit L-30D coating (figures
11.14 and 11.15).Higher coating levels (25-35%) of
Eudragit L-30 acted as an extra barrier and delayed the
release of the vaccine during dissolution studies.
To produce enteric coatings, a 3-5 mg application of
Eudragit L-30D per cm2 surface area of VA LS 1-74 loaded
sugar beads is suggested by the manufacturer's product
prospectus (Rohm Pharma, Weiterstadt, West Germany).
This agrees with the theoretical calculation: -
mass of non-pareil sugar beads = 62 mg/100 beads
density (150 g/175 cm3)
diameter (calculated)
surface area
= 0.857 g/cm3
= 0.89 cm
= 0.0253 cm
2/0.62 mg
15% w/w of Eudragit L-30D coating gives 3.68 mg110T
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Dissolution of various levels of Eudragit L-30D coated
and 10% Vibrio anguillarum loaded sugar bead vaccine (%
release vs. time profile) in U.S.P. simulated gastric
fluid of pH 4.5 for the first 1 hour and then in
U.S.P. simulated intestinal fluid of pH 7.2.109
Table 11.17 In Vitro Dissolution of VA LS 1-74 from 10% Vibrio
Loaded and 15% Eudragit L-30D Coated Vaccine Beads
at Different Pretreatment Time in Simulated
Gastric Fluid.
Dissolution
Time
Mean Percentof Releaseda+ SDb
1c 2 3e
0min 8.6±2.2 9.2± 0.4 5.1± 0.9
15min 40.2±7.2 8.7± 3.1 5.1± 0.9
30min 83.211.0 66.4± 9.8 37.7± 4.0
45min 88.6±6.8 83.7±10.8 62.8± 8.2
1hr 94.3±6.9 96.1± 3.9 74.3±10.7
2hr 98.6±6.2 92.6± 2.5 82.6±11.9
3hr 108.9±9.4 94.9± 5.1 84.2± 6.4
5hr 102.9±6.3 95.5± 6.8 88.9± 9.1
11hr 100.0±0.0 100.0± 0.0 100.0± 0.0
aMean valueof three replicates
b Standard deviation values for eachmean percent
b pretreated in simulated gastricfluid for2hours
d pretreated in simulated gastricfluid for4hours
e pretreated in simulated gastric fluid for6hours110
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Dissolution of various levels of Eudragit L-30D coated
and 25% Vibrio anguillarum loaded sugar bead vaccine (%
release vs. time profile) in U.S.P. simulated gastric
fluid of pH 4.5 for first 1 hour and then in U.S.P.
simulated intestinal fluid of pH 7.2.111
Table 11.18 In Vitro Dissolution of VA LS 1-74 from 25% Vibrio
Loaded and Various Levels of Eudragit L-30D Coated
VaccineBeads.
Dissolution
Time
Mean Percent of Releaseda + SDb
1 26 3e 4f
15 min 3.0± 0.2 1.1± 0.3 1.3± 0.3 0.5± 0.0
30 min 6.0± 0.7 1.2± 0.3 2.0± 0.3 1.7± 1.4
45 min10.0± 1.0 1.9± 0.8 2.7± 0.6 5.0± 3.9
1.25 hr20.5± 2.5 6.7± 0.9 11.3± 1.618.2±11.2
1.5 hr42.6± 3.0 36.2± 7.233.8± 2.624.6± 4.4
1.75 hr66.6± 5.1 64.0±17.148.4± 1.442.8± 6.5
2 hr 86.1± 1.5 73.1±18.259.8± 7.959.5±10.0
3 hr 89.4± 3.174.2±12.573.1± 5.469.6± 8.3
4 hr 87.6± 1.6102.2± 9.7 81.3± 2.889.6± 4.1
6 hr 89.9± 1.093.0± 9.090.1± 7.698.1± 7.0
12 hr 100.0± 0.0100.0± 0.0100.0± 0.0100.0± 0.0
aMean value of three replicates
b Standard deviation values for eachmean percent
C5%Eudragit L-30Dcoating
d15%Eudragit L-30Dcoating
e25%Eudragit L-30Dcoating
f35%Eudragit L-30Dcoatingr-
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Eudragit L-30D per cm2 and was the optimum loading for
formulating the vaccine.
Effects of prolonged gastric fluid pretreatment
Because delayed gastric emptying or prolonged gastric
acid exposure may affect the release pattern of a drug, this
effect was investigated by pretreating our vaccine beads in
pH 4.5 simulated gastric fluid for different periods of
time.It was found that the longer the pretreatment time,
the slower was the dissolution rate was (figure 11.16).It
took an increasingly longer time (8 to 20 minutes) to
release 50% of our vaccine when acid pretreatment time
increased from 2 to 6 hours (figure 11.17).The increased
release time can be explained by the observation that
vaccine beads would clump together to form a large mass in
the acidic medium over an extended period of time.As a
result, the surface area exposed to the surrounding
dissolution media decreased and dissolution was slowed.
However, it was found that this clump would re-dissolve in
simulated intestinal fluid, at the higher pH of 7.2.1101
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Table 11.19 In Vitro Dissolution of VA LS 1-74 from 10% Vibrio
Loaded and Various Levels of Eudragit L-30D Coated
Vaccine Beads.
Dissolution Mean Percent of Releaseda + SDb
Time lc 2d 3e 4f
15 min 6.7± 0.5 0.5± 0.5 0.0± 0.0 0.9± 1.0
30 min12.1± 1.6 2.2± 1.0 0.0± 0.0 0.6± 1.9
45 min13.5± 1.6 4.6± 0.5 0.0± 0.0 2.7± 2.4
1.25 hr14.9± 4.8 4.6± 0.6 0.0± 0.0 5.5± 3.4
1.5 hr 54.7±13.641.1± 0.923.4± 5.031.1± 6.1
1.75 hr80.1± 4.9 61.5± 7.4 62.3± 8.262.1± 5.9
2 hr 88.6± 6.879.1± 5.5 66.6± 9.864.3± 6.3
3 hr 85.8± 5.687.1± 6.774.7± 6.663.8± 1.0
4 hr 88.3± 6.385.0± 7.582.9± 5.176.0± 1.4
6 hr 95.7± 3.896.2± 6.689.8± 1.789.4±10.5
12 hr100.0± 0.0100.0± 0.0100.0± 0.0100.0± 0.0
a Mean value of three replicates
bStandard deviation values for each mean percent
c 5% Eudragit L-30D coating
d 15% Eudragit L-30D coating
e 25% Eudragit L-30D coating
f 35% Eudragit L-30D coating-,1-
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CONCLUSIONS
Eudragit L-30D provides a good enteric coating and
protects the vaccine from being released until the
surrounding pH rises above 5.5.
The amount of VA LS 1-74 loading will affect the
dissolution rate and the optimum level of vaccine loading
for rapid release is 10%.
Eudragit L-30D coating level also affects the
dissolution rate.Optimum coating level found for enteric
protection against stomach acid was about 15%.
Prolonged pretreatment of enteric coated vaccine beads
in simulated gastric fluid for more than 2 hours causes
aggregation of the vaccine beads and delays the release of
vaccine.119
ENDNOTES
1the -70°C freezer was located in Room 78 in the basement of
Department of Microbiology, Nash Hall, OSU, Corvallis
2 Difco Pharmaceuticals, Michigan, U.S.A.
3Sigma Chemical Company, St. Louis, Missouri, U.S.A.
4Paulaur Corp., Princeton, New Jersey, U.S.A.
5Rohm Pharma, Weiterstadt, West Germany
6 Sigma Chemical Company, St. Louis, Missouri, U.S.A.
7 Matheson Coleman and Bell, Division of the Matheson Company
Inc., Nerwood, Ohio, U.S.A.
8 Sigma Chemical Company, St. Louis, Missouri, U.S.A.
9 Sigma Chemical Company, St. Louis, Missouri, U.S.A.
10Sigma Chemical Company, St. Louis, Missouri, U.S.A.
11Sigma Chemical Company, St. Louis, Missouri, U.S.A.
12Sigma Chemical Company, St. Louis, Missouri, U.S.A.
13 Model #ASO1T26G7R, AMSCO laboratory, American Sterilizer
Co., Erie, Pennsylvania, U.S.A.
14 Shakers from various companies are located on fifth floor
of Nash Hall, Department of Microbiology, Oregon State
Univeristy, U.S.A.
15 prepared from dextrose purchased from Sigma Chemical
Company, St. Louis, Missouri, U.S.A.
16Sigma Chemical Company, St. Louis, Missouri, U.S.A.
17 Sigma Chemical Company, St. Louis, Missouri, U.S.A.120
18 SorvallRRC-5B Refrigerated Super Speed Centrifuge, DuPont
Instruments
19 Sigma Chemical Company, St. Louis, Missouri, U.S.A.
20Sigma Chemical Company, St. Louis, Missouri, U.S.A.
21 Galaxie Osterizer blender, ULR listed 564A, Mexico
22Lab-Line/PRL, Melrose Park, Illinois, U.S.A.
23 Miniplus II peristaltic pump, Gilson Medical Electronics,
Middleton, Wisconsin, U.S.A.121
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CHAPTER III
IN VIVO CHALLENGE TEST AND ANTIBODY LEVELS
AFTER VACCINATION127
ABSTRACT
An oral enteric-coated Vibrio anguillarum (LS 1-74)
vaccine was formulated by initially coating lyophilized
bacteria (10% w/w) onto sugar beads (18-20 mesh or 1.00 +
0.06 mm).A methacrylic acrylic acid copolymer (Eudragit L-
30D) coating (15% w/w) was applied to serve as an enteric
coating.Vaccine efficacy was determined by both an in vivo
challenge with live bacteria and measurements of serum and
mucus antibody levels by ELISA.Survival rates among the
test group, positive and negative controls were 80.3%, 83.3%
and 70.3%, respectively.Serum and mucus antibody levels
were found to be significantly greater (8-32 times greater
in the serum and 1.4-1.8 times greater in the mucus) in the
test group (p<0.001).Serum and mucosal antibody levels are
better indicators for the evaluation of the efficacy of an
oral vaccine than the survival rate.Using this formulation
technique to develop other oral vaccines or to deliver acid-
labile proteins is promising.128
INTRODUCTION
Outbreak of bacterial disease has always been a threat
to fish farming and most farmers are willing to pay extra
costs to vaccinate their fish against potential infections
(1).However, despite over 40 years of effort there are
only a few commercially available bacterial fish vaccines
(2) for the control of enteric redmouth, furunculosis and
vibriosis.These vaccines are mostly administered by
immersion or spray methods (3,4,5,6) while the oral route of
administration does not provide good protection.
In a postal survey, the amount of money that
experienced farmers were willing to pay for 100% vaccine
efficacy was positively correlated with the average annual
vibriosis mortality rate (1).New farmers who had
experiences with vibriosis were prepared to pay
substantially more for vaccination than were vibriosis-free
farmers.If younger fish were guaranteed vibriosis-
resistant, most farmers who indicated an initial preference
for rearing older fish, would instead purchase the younger
fish (fingerlings or yearlings).All farmers are prepared
to pay at least the full cost of vaccination for this
protection.
Oral vaccination at present is not as effective as
injection or direct immersion.However, it has certain
advantages over other methods of vaccination.These include
no stressful handling and no break in routine because129
vaccine can be incorporated into the fish feed and fed to
the fish during routine husbandry.Also, oral vaccination
was the first (7,8,9) and the preferred route if possible
for mass vaccination to protect fish against vibriosis
because there is no size limitation and because of reasons
mentioned above.
Since 1960 oral vaccines against vibriosis have been
studied for more than three decades by Japanese (Endo, 1961
and Hayashi, 1964) and American investigators (Nelson,
Fryer, Fletcher and White, 1973; Rohovec, 1975) using either
formalin-killed and/or lyophilized whole cells of Vibrio
anguillarum (10).In 1972 Fryer et al.(11) found
significant protection in chinook salmon from orally
administered, formalin-killed, lyophilized sonicates of V.
anguillarum.As little as 200 micrograms per fish per day
for 20 days was sufficient for immunization.Natural
challenges resulted in a 95% loss in control group versus
37% in test group but booster feedings did not provide
increased protection.
In 1975 Rohovec et al.(12) administered orally
formalin-killed wet-packed or formalin-killed lyophilized
whole cells of Vibrio anguillarum to salmon.Concentrations
ranging from 0.5 to 10 mg wet weight of vaccine per gm of
ration were effective in controlling vibriosis.Increasing
the number of consecutive days the oral vaccine was
administered from 10 to 45 days did not increase the degree
of protection.Agglutinating antibodies were detected in130
parenterally vaccinated fish but not in orally immunized
fish (12).
In 1983, lipopolysaccharide fraction extracted by
Westphal's method from the formalin killed bacterin was used
as an extracted vaccine (13).Lipopolysaccharide, a heat
stable antigen in the cell wall was found to be an effective
immunogen.Oral bacterin against vibriosis in cultured ayu
showed that fish were effectively immunized with heated
bacterin and that agglutinin secreted in the body surface
mucus of the immunized fish preventedpathogenic bacterium
Vibrio anguillarum from adhering to the skin of fish (13).
These findings suggested that a heat stable antigen on the
surface of the bacterium can be used to form a vaccine
against vibriosis.
Although oral vaccination has been shown to provide a
degree of protection, oral vaccines were significantly less
effective than intraperitoneal injections (4).In 1983,
Agius et al.(14) compared an extract antigen with whole
cell bacterins administered to rainbow trout
intraperitoneally or orally in food.Intraperitoneal
vaccination resulted in virtually 100% protection within 2
weeks whereas oral vaccination resulted in maximum
protection of 50% to 70% after 8 weeks.When administered
orally, formalin killed cells were better than extracts.
This result was supported by data from experiments on how
antigen uptake in fish occurs during the vaccination process
(15) .131
Smith (15) used various radiolabelled proteins and
latex particles sensitized with radiolabelled proteins to
compare hyperosmotic infiltration and bath methodsfor fish
vaccination.While there was some uptake of soluble
proteins using the bath method, uptake was greatly increased
when the proteins were in the particulate form.Size of an
antigen was concluded to be an important factor for
immunization.
However, the major problem of oral vaccination resides
on the delivery of antigens to certainpositions of the fish
gut where immune responses can be elicited.A number of
studies were performed to help understand the basic
physiology and immunology of fish.While antigen uptake
through the gill is implicated for vaccination by immersion
(16,17), pinocytosis (18) and processing of antigens by
epithelial cells and macrophages (19,20,21) were observed in
several teleosts and in particular, the second gut segment
of carp when antigens were administered orally.McLean et
al (22) confirmed that the fish gut is able to absorb and
subsequently transfer macromolecules to the bloodstream and
tissues.This implies if the fish can absorb orally
administered intact proteins, systemic immune response can
occur.
High acid concentration in the stomach may denature or
inactivate the orally administered vaccine or antigens
before the vaccine reaches the second gut.Vaccine
degradation by stomach acid is supported by increased132
protection against vibriosis after anal intubation of the
vaccine (23).Systemic and mucosal immune response can also
be observed when Vibrio anguillarum was deposited to the
second gut by anal administration (24).
In 1989, Lillehaug (25) formulated two oral Vibrio
vaccines that were protective against digestive degradation.
One of these contained 30% lyophilized Vibrio anguillarum in
a slow-release matrix and the other consisted of 20%
lyophilized whole-cell granules coated with 10% Eudragit L
for enteric protection against stomach acid.In vivo
challenge of live bacteria showed higher mortality rates in
the fish that were given these slow-release or enteric
coated vaccines than unprotected vaccines.The author
explained the lack of immune response by the slow release
and enteric-coated vaccine by the reduction in absorption of
lipopolysaccharide antigens by the fish.The
lipopolysaccharide antigen is located on the surface of
vibrio.Also, lipopolysaccharides are usually not
deactivated by the stomach acid.
The ultimate goal of this study was to formulate an
oral vibrio vaccine that can withstand the high acid
environment of fish stomach and be released rapidly in the
second segment of the fish gut for absorption to stimulate
both systemic and local (mucosal) immune response.In the
previous two chapters, the importance of fish gut
physiology, immunology, and pH's along the gastrointestinal
tract have been discussed in regards to formulation of a133
vaccine. The most optimum antigen loading level and enteric
coating thickness for protection were presented.
The objectives of this final chapter include an in vivo
challenge of live bacteria in the test group, positive and
negative controls to assess effectiveness of the vaccine.
Using ELISA, both serum and mucus antibody levels were
measured after vaccination and an in vivo challenge
performed to evaluate the effectiveness of the vaccine.A
better predictor of vaccine efficacy was found to be
antibody levels after in vivo challenge rather than
comparing mortality rates during in vivo challenge.
Discussions of the prospects of an oral enteric coated
vaccines and the potential application in human and animal
diseases are presented.MATERIALS AND METHODS
Materials
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Vaccines for the test group
Thevaccine used during the in vivo challenge test
contained 10% (w/w) of VA LS 1-74 and 15% (w/w) of Eudragit
L-30D1.The vaccine was incorporated into Oregon Test Diet
(OTD)2 and fed to the fish directly for 30 days.
Unprotected vaccines for the positive control and negative
control group
Unprotected or non-enteric-coated vaccine for the
positive control group was formed by embedding lyophilized
whole cells of VA LS 1-74 directly into OTD2.Fish in the
negative control group were fed with plain OTD2.
Fish for in vivo challenge
Experimental fish were Coho salmon (Oncorhynchus
kisutch) donated by Oregon hatcheries and the Oregon
Department of Fish and Wildlife (ODFW).Each fish weighed
about 80 grams.
Holding facility
Oral vaccination took place in the old Fish Disease
Laboratory on Highway 20 while the new Salmon Disease
Laboratory was being built.In January 1990, the new Salmon
Disease Laboratory was open and the fish were transported to135
the new facility where the in vivo bacteria challenge
occurred and serum and mucus samples were taken for antibody
assays.The Salmon Disease Laboratory is a 9,000 ft2
facility.Pathogen-free water is provided from two wells
each 48 feet deep.The water goes through a column where
excess gas is eliminated and supplemental oxygen is added to
a concentration of 10 ppm.Water temperature is maintained
at 12.5°C and effluent from the wet laboratory is treated
with chlorine to ensure that no infectious agents used in
the laboratory exit via the water.The capacity of each
tank used during the experiment was 100 L and 25 fish were
put into each tank.
ELISA reagents
Vibrio antigens were prepared by research assistants in Dr.
Stephen Kaattari's Laboratory (Nash Hall, Oregon State
University, Corvallis).Three antigens were chosen with the
following abbreviations throughout the study (table III.1).
(i) VAE.PT = Vibrio antigen extract prepared by Prasad
Turaga
(ii)VAE.DC = Vibrio antigen extract prepared by Don Chen
(iii) LPS= lipopolysaccharide antigen
Bovine serum albumin3 (BSA)
Biotin-labelled anti-fish antibody (1-14 or WARR's)
1-14 is a mouse monoclonal antibody developed by Dr. G.
Warr from University of South Carolina.Stock 1-14 solution
was obtained from Dr. Kaattari's research assistant (Nash136
Table III.1Abbreviations for Various Antigens and Reagents
Used During ELISA.
(i) VAE.PT= Vibrio antigen extract prepared by Prasad
Turagaa
(ii) VAE.DC= Vibrio antigen extract prepared by Don
Chena
(iii)LPS = lipopolysaccharides antigen
(iv) BSA = bovine serum albumin
(v) WARR's= mouse monoclonal antibody 1-14 developed by
(1-14) Dr. G. Warr
(vi) SA.HRPO = strepavidin-horsradish peroxidase
(vii)ABTS = azino-bis(ethylbenzthiazoline-6-sulfonic
acid)
(viii) TBS = tris buffer saline
(ix) T-TBS= tween-tris buffered saline
(x) SAS = saturated ammonium sulfate
(xi) PBS = phosphate buffered saline
a Prasad Turaga and Don Chen were research assistants of Dr.
Stephen L. Kaattari, Department of Microbiology, Nash
Hall, Oregon State University, Corvallis.137
Hall, Oregon State University, Corvallis).
Strepavidin-Horseradish Peroxidase (SA.HRP0)4
Strepavidin-HRPO was purchased in the lyophilized form and
2.5 ml of sterile water was injected into the 0.25 mg vial,
which has an activity of 130 units/mg.
Substrate solution
Ten ml of citric acid buffer (table 111.2), 5 ml of H2025
and 75 ul of ABTS6 (10 mg/ml of 2,2 azino-
bis(ethylbenzthiazoline-6-sulfonic acid) are mixed together
in distilled water.
ELISA equipment
Equipment consisted of ELISA plates7, tupperware containers
as moist chambers for incubation, ELISA platereaders,
parafilm for wrapping ELISA plates during incubation to
avoid excessive loss of evaporation, and wet paper towels to
maintain moisture content inside incubation chamber.
Methods
Vaccination procedures
A total of 225 Coho salmon (Oncorhynchus kisutch) each
weighing about 80 grams were put into nine tanks with 25
fish in each tank.Of the nine tanks, three tanks were
chosen randomly to be the test group, three to be the
positive and three to be the negative controls (see table
111.3 for the assignment of each group and corresponding
tank numbers).All the fish were fed with regular OTD and138
Table 111.2Buffers Used in ELISA.
1. Coating buffer
Na2CO3a 1.59 g
NaHCO3a 2.93 g
NaN3a 0.20 g
H2O q.s. 1000 ml
Adjust pH to 9.6 and store no longer than 2 weeks at 4°C.
2. Tris buffer saline (TBS)
Trizma basea 6.07 g
EDTAa 0.37 g
NaCla 8.70 g
H2O q.s. 1000 ml
Adjust pH to 8.0.
3. Tween tris buffered saline (T-TBS)
Add 1% (v/v) of tween 20a to Tris buffer saline (TBS).
4. Citric acid buffer
Prepare a 0.2% w/v of citric acida and adjust pH to 4.0.
a The Sigma Chemical Company, St. Louis, Missouri, U.S.A.139
Table 111.3Allocation of Fish in Each Group During Oral
Vaccination and In Vivo Challenge.
Tank number
1
Assigned group
(Not Used)
Number of fish
0
2 positive control 25
3 positive control 25
4 positive control 25
5 negative control 25
6 negative control 25
7 negative control 25
8 test group 25
9 test group 25
10 test group 25
Total= 225140
acclimated in their tanks for a month before vaccination
trials started in order to avoid stress and palatability
problems.During the vaccination period, each fish in the
test and positive controls was given daily 3 mg of
lyophilized VA LS 1-74 in the form of enteric coated beads
or unprotected vaccine, respectively.Same amount of OTD
was given to the negative control group.Vaccination period
continued for a total of 30 days.
In vivo challenge
Live bacteria challenge took place 47 days after the
last administration of oral vaccine.Water supply was
turned off and water level brought down to one inch above
the dorsal fin of most fish in the tank.One liter of VA LS
1-74 with an optical density (O.D.) of 1.5 was then added to
each tank.After 20 minutes the water level was slowly
returned to the original level by turning on the water
supply again.Mortalities were collected daily after
challenge and vibriosis was confirmed by culturing live
bacteria from the dead fish kidney.The bacteria were
examined alive or after Gram's stain under the microscope.
Methods of collecting serum and mucus samples for ELISA
Serum and mucus samples were collected from surviving
fish for antibody assays 34 days after the initiation of
live bacteria challenge.
Mucus samples from fish in each tank were expressed and141
collected in a clear plastic bag containing 20 ml of water.
To do this, each fish from a particular tank was put into
the same bag for 30 seconds before skin mucus was wiped off
by the inside surface of the bag.
Serum samples were then immediately after mucus samples
were obtained.After euthanasia, the caudal peduncle was
severed diagonally to allow blood samples to be collected
into small centrifuge tubes.After storage at 4°C
overnight, the serum was removed from the clot and residual
red blood cells were removed by 20 second centrifugation in
a microfuge9The serum was kept at -20°C until being
assayed for antibodies by ELISA.
After centrifugation at 2500 rpm10 (750 x g) for 10
minutes, the mucus protein was concentrated by saturated
ammonium sulfate (SAS)(see SAS precipitation protocol in
the next section) and dialyzed againstPBS11 (phosphate
buffered saline) to become more concentrated.Protein
contents were determined by Lowry's assay method (refer to
chapter II) before antibody levels were measured by ELISA.
Standard serum and mucus samples were obtained from
previously immunized Coho salmon while control serum and
mucus samples were taken from Coho salmon that had never
been exposed to Vibrio anguillarum antigens.
SAS precipitation protocol for concentrating mucus samples
An equal volume (5 ml) of saturated ammoniumsulfatel2
(approximately 70 g/100 ml at 25°C) was added slowly to the142
mucus sample (5 ml) over 30 minutes.Precipitate was
collected after centrifuging at 3,000 rpm13 (1100 x g) for
30 minutes, and resuspended in 5 ml of H2O.This procedure
was repeated one more time and the precipitate was
resuspended in a minimal amount of PBS11.These samples
were then dialyzed against 1 liter ofPBS11 overnight in a
4°C cold room for a total of three times.
ELISA procedure (table 111.4)
Because ELISA consisted of several steps involving
different reagents, various concentrations of different
antigens (VAE.PT, VAE.DC and LPS), WARR's (1-14) and SA.HRPO
were tested to determine the optimum conditions for the
ELISA assay.The first part of the "results and discussion"
section in this chapter describes the steps in developing
the protocol.A brief description of the final protocol
(table III.d) is as follows:Each well of a Elisa plate was
coated with 100 ul of VA extract that was previously
prepared and diluted to one one-hundredth of its original
concentration using a coating buffer (table 111.2).The
plate was covered with parafilm and incubated in a
tupperware container overnight at 17°C.After removal of
the coating solution, 200 ul of 1% bovine serum albumin in
tween tris-buffered saline (T-TBS, see table 111.2) were
added and the plate was incubated in the same manner for 1.5
hours at 37°C.The plate was then washed three times with
T-TBS.In a series of three steps, 100 ul of diluted serumTable 111.4Procedure of ELISA.
Step Reagent Dilution in
T-TBS
Amount Incubation
times
Temp.
1. antigenb 1/100c 100 ul overnight 17°C
2. BSA 1% 200 ul 1.5 hr 37 °C
3. sera/mucus varies 100 ul 1.5 hr 17°C
4. WARR's (1-14) 1/1000 100 ul 1.5 hr Room
5. SA.HRPO 1/200 100 ul 1.5 hr Room
6. Substrate undiluted 100 ul none
7. Read O.D. at 405 nm every5minutes.
a Steps 2 to 5 are followed by three washes of T-TBS using a squirt bottle.
bVAE.PT was chosen to be our antigen instead of VAE.DC or LPS in our final assays.
c Antigens were diluted in coating buffer (table III.b).144
or mucus sample, 100 ul of 1/1000 dilution of WARR's
solution and 100 ul of 1/200 dilution of Strepavidin-HRPO
were added. The incubation time for each of these three
steps was 1.5 hours, followed by three washes of T-TBS.The
incubation temperature was 17°C for the serum or mucus
samples and room temperature (20°C) for WARR's (1-14)
solution and Strepavidin-HRPO.The final step was the
addition of 100 ul of the substrate solution (containing
citric acid buffer, H202 and ABTS, see Materials) and the
O.D. was periodically measured and recorded by an ELISA
reader at 405 nm.
Statistical analysis
To evaluate any significant difference of the serum and
mucus antibody levels among the three groups of fish, an
analysis of variance was performed in additional to multiple
group comparison using Tukey's HSD method and confidence
intervals.145
RESULTS AND DISCUSSION
In vivo challenge of live bacteria
Fish began to die of vibriosis on day 5 and continued
to die till day 18 after challenged with live bacteria (Fig.
III.1).Although the test group had a higher survival rate
than the negative control group (80.3% or 57/71 vs 70.3% or
52/74 ), slightly more fish died in the test group than the
positive controls (19.7% or 14/71 vs 16.7% or 12/72
mortalities).There were less than 75 fish in each group
during the live bacteria challenge because some fish were
infected with cold water bacterial disease during the
vaccination period and were removed from the study.The
results of the survival challenge test do not provide
evidence that enteric protected vaccine was better than the
unprotected non-enteric coated vaccine.Measurement of the
serum and mucus antibody levels to detect differencesin the
antibody levels among the fish in the test group, positive
and negative controls was performed.However, there was no
standard ELISA protocol for antibodies against Vibrio
anguillarum.
The first task in determining serum or mucus antibodies
in Coho salmon (Oncorhynchus kisutch) would be the
optimization of reagent concentrations and incubation times
in each step of ELISA.The following section can serve as a
guideline during a need to develop a new antibody assay
using ELISA method.105k
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Humber of days
Percent survival rate after in vivo challenge oflive
Vibrio anguillarum after oral vaccination.The vaccine
(test) group has a survival rate of 80.3% or 10%higher
than the survival rate in the control group.147
Development of an ELISA protocol for antibodies against VA
LS 1-74
As noted in table 111.4, ELISA for antibodies consists
of several steps involving an antigen, bovine serum albumin
(BSA), serum or mucus samples, mouse monoclonal anti-fish
antibody (WARR's) and strepavidin-horseradish peroxidase
( SA.HRPO).The first step in developing the assay would be
the selection of an appropriate antigen.
Selection of an antigen
Two Vibrio anguillarum extracts were chosen (VAE.PT and
VAE.DC) and prepared by Prazad and Don Chen, research
assistants of Dr. Stephen L Kaattari, Department of
Microbiology, Oregon State University, Corvallis, Oregon)
and a Vibrio anguillarum lipopolysaccharides (LPS) fraction.
To compare the effectiveness of an antigen, the
addition of antibody to the ELISA plate in the second step
can be skipped.Antigens that are of higher concentrations
or higher binding affinity to the ELISA platewill bind in a
larger quantity and more closely onto the ELISA plate.As a
result, less WARR's will bind to the ELISA plate and
subsequently less SA.HRPO and substrate will react together
in the final step to give a smaller value of absorbance.
Figure 111.2 shows the absorbance of different antigens
at various dilutions.LPS did not show any binding
abilities to the ELISA plate in any range of dilutions.On
the other hand, VAE.PT and VAE.DC gave the best binding
capacity at about 1% dilution. To choose between VAE.PT and1.2--
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Figure 111.2 O.D. vs. antigen concentration in phosphate buffered
saline to compare the binding abilities of three
different antigens (VAE.PT, VAE.DC and LPS) to ELISA
plate. VAE.PT gave the best O.D.- concentration profile.149
VAE.DC, the protein contents in each of these antigens were
first measured using Lowry's protein assay.Figure 111.3 is
a calibration curve of Vibrio anguillarum antigens
concentrations using bovine serum albumin as a standard.
Figure 111.4 compares the binding abilities of VAE.PT
and VAE.DC on the basis of same protein content.The
absorbance increase was observed after 5 and 10 minutes and
the results were very consistent.Because VAE.PT resulted
in a smoother curve and slightly larger drop in absorbance
in the dilution range of 1/10 to 1/100,000, VAE.PT was
chosen to be the antigen for the ELISA assay.1/10 and
1/100 dilution factors were used in later experiments to
determine the optimum concentrations for other reagents.
Optimization of antigen, WARR's and SA.HRPO
concentrations
To identify the best dilution factor for each reagent,
two different concentrations were selected for each reagent
(table 111.6) and the ELISA assay was conducted with both
standard immunized (STD) and normal non-immunized (NS) sera
(figure 111.5). Using the same amount of each reagent,
VAE.PT gave a much better result than VAE.DC.All of
samples 3 to 6 had a higher absorbance in the standard
immunized sera (STD.VAE.PT) than normal non-immunized sera
(NS.VAE.PT).On the other hand, only sample numbers 1,5 and
7 gave slightly higher absorbance in the immunized sera
samples when VAE.DC was used.This again suggested that
VAE.PT should be used in the ELISA.Dilution factors asFigure 111.3
Concentration (mg/m1)
Calibration curve for Vibrio anguillarum antigens in
phosphate buffered saline using bovine serum albumin as
standard.Absorbance vs. concentration with line
estimated from linear regression.151
Table 111.5Calibration Curve Data for Vibrio Anguillarum
Antigen Concentration Estimated Using Linear
Regressiona.
Std. No.Conc.
(mg/m1)
Absorbance
Inv. Est.
Conc.b %
(mg/ml)
Theoryc
1 0.01 0.000 0.005
2 0.05 0.016 0.045 89.3
3 0.10 0.040 0.102 101.9
4 0.50 0.512 0.517 103.3
5 1.00 0.409 0.991 99.1
Mean 98.4
S.D. 6.3
%C.V.d 6.3
a R2 =0.9995
bInversely estimated concentration = 0.006+ 2.410X
(Absorbance)
c % Theory = (Inversely estimated concentration/known
concentration) x 100
d % Coefficient of variation = (S.D./Mean) x 1000
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O.D. vs antigen concentration in phosphate buffered
saline to compare the binding abilities of different
antigens (VAE.PT and VAE.DC) to ELISA plate. VAE.PT has r.)
a better binding ability.153
Table 111.6Dilution Factors of Various Reagents in Figure
111.5 to Find the Optimum Concentrations for
ELISA Assay.
SampleNo. Antigena WARR'SbSA.HRPOb
1 1/10 1/20 1/30
2 1/100 1/20 1/30
3 1/10 1/100 1/30
4 1/100 1/100 1/30
5 1/10 1/20 1/100
6 1/100 1/20 1/100
7 1/10 1/100 1/100
8 1/100 1/100 1/100
a 200 ul of diluted antigen was used to coat the ELISA plate
b100 ul of diluted reagent was used in each specific step.0.16-
0.14-
0.12
0.10-
0.08-
0.06
0.04-
00.02-
0.00
0 1
$
X
A
A
A
A
A
A
V
2 3
S
A
A
A
4
A. A
STD.VAE. PT
NS.VAE.PT
STD.VAE.DC
NS.VAE.DC
0
8
5 7
Various antigens and reagents concentrations
Figure 111.5
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ELISA on standard immunized sera (STD) and normal non-
immunized sera (NS) using different antigens (VAE.PT or
VAE.DC) and various amounts of SA.HRPO, WARR's.Table
111.6 lists the exact amount of each reagent used.155
high as 1/100 for both WARR's and SA.HRPO were still
effective in distinguishing immunized from non-immunized
serum.
To minimize the amount of each reagent used, further
dilution of the reagents and the WARR's in 1% bovine serum
albumin were performed (table 111.7 and 111.8).Figures
111.6 and 111.7 are ELISA results for non-immunized and
immunized sera, respectively.All the curves for the non-
immunized sera did not show any significant increase in
absorbance implying minimal amount of antibodies existed in
non-immunized sera against the selected Vibrio antigen
(VAE.PT).The amount of standard immunized sera gave higher
absorbance values suggesting the presence of antibodies
against the Vibrio antigen.
Conditions in sample #4 (1/100 dilutions of antigen,
1/1000 dilutions of WARR's, 1/200 dilutions of SA.HRPO) gave
the best ELISA result with small and minimal increase in
absorbance for non-immunized sera while a significant change
of absorbance was obtained over a range of serum quantity
(Figure 111.8).A summary of the final ELISA protocol is
listed in table 111.4 in the Materials and Methods section
of this chapter.
Serum antibody assay
Two typical ELISA curves of standard serum samples from
previously immunized Coho salmon are shown in figure 111.9.
The 50% point of the O.D. range was consistently given by 1156
Table 111.7Dilution Factors of Various Reagents in Figure
111.6 to Find the Optimum Concentrations for
ELISA.
SampleNo. AntigenaWARR'SbSA.HRPOb
1 1/100 1/100 1/100
2 1/100 1/100 1/200
3 1/100 1/1000 1/100
4 1/100 1/1000 1/200
5 1/100 1/1000c 1/100
a 200 ul of diluted antigen (Vibrio anguillarum extract) was
used to coat the ELISA plate
b100 ul of diluted reagent was used in each specific step.
c 1% BSA (bovine serum albumin) was used to diluteinstead
of TTBS (tween 20 in tris-buffered saline)157
Table 111.8Dilution Factors of Various Reagent in Figure
111.7 to Find the Optimum Concentrations for
ELISA.
SampleNo. Antigena WARR' SbSA.HRPOb
1 1/100 1/100 1/100
2 1/100 1/100 1/200
3 1/100 1/1000 1/100
4 1/100 1/1000 1/200
5 1/100 1/1000c 1/100
a 200 ul of diluted antigen (Vibrio anguillarum extract) was
used to coat the ELISA plate
b 100 ul of diluted reagent was used in each specific step.
c 1% BSA (bovine serum albumin) was used to dilute instead
of TTBS (tween 20 in tris-buffered saline)0.16
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Typical ELISA curve obtained from standardimmunized
sera.1 ul gives about 50% maximum responseand is
assigned to have 1 antibody unit.162
ul of the standard serum, which was arbitrarily assigned to
be 1 antibody unit.In other words, 1 ml of the standard
serum is equivalent to 1,000 antibody units.An amount
equivalent to 1 ul of standard serum was then added to each
Elisa plate during assay to serve as a reference for the
determination of antibody levels of various samples.
Figure III.10 showed a preliminary result of some
immunized serum and mucus samples from a fish in tank #9 of
the test group.The ELISA curve of the serum sample was
similar to that of the standard immunized serum, indicating
that a significant amount of antibodies existed in the
serum.On the other hand, the mucus sample from immunized
fish did not suggest the presence of any antibodies when
compared to the result observed from non-immunized serum.
However, it was later discovered that the antibodies in the
mucus samples were too dilute to be detected.
Figures III.11 to 111.19 are ELISA results of sera
samples from fish in different tanks.The horizontal line
represents the O.D. given by 1 ul of standard immunized
serum of Coho salmon on the same ELISA plate.As has been
mentioned before, standard immunized sera was arbitrarily
assigned to have 1 antibody unit (equivalent to 1000 units
per ml).For example, figure 111.14 illustrates Elisa
results of 5 fish in a negative control tank #5.The
horizontal line represents the O.D. value of the standard
serum and it required an average 3 ul of sample serumin
each fish to attain the same O.D. value.As a result, the0.35
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Figure III.10First ELISA on standard immunized sera, immunized sera
and mucus from tank #9 (test group) and normal non-
immunized sera.01
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Figure III.11ELISA result on positive control sera from fish in tank
#2 (878 ± 256 units/ml) .The horizontal line represents
the O.D. increase of 1 ul standard immunized serum which
was arbitrarily assigned to be 1 antibodyunit/ul.N4J
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Figure 111.12ELISA result on positive control sera from fish in tank
#3 (3135 + 1600 units/ml).The horizontal line
represents the O.D. increase of 1 ul standard immunized
serum which was arbitrarily assigned to be 1 antibody
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Figure 111.13ELISA result on positive control sera from fish in tank
#4 (3580 + 2200 units/ml).The horizontal line
represents the O.D. increase of 1 ul standard immunized
serum which was arbitrarily assigned to be 1antibody
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Figure 111.14ELISA result on negative control sera from fishin tank
#5 (412 + 44 units/ml).The horizontal line represents
the O.D. increase of 1 ul standard immunized serumwhich
was arbitrarily assigned to be 1antibody unit/ul.0.45
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Figure 111.15ELISA result on negative control sera from fish in tank
#6 (454 + 179 units/ml).The horizontal line represents
the O.D. increase of 1 ul standard immunized serum which
was arbitrarily assigned to be 1 antibody unit/ul.0,05
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Figure 111.16ELISA result on negative control sera from fish in tank
#7 (985 + 164 units/ml) .The horizontal line represents
the O.D. increase of 1 ul standard immunized serum which
was arbitrarily assigned to be 1 antibodyunit/ul.0.187
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Figure 111.17 ELISA result on test group sera from fish in tank #8
(35740 + 11180 units /ml).The horizontal line
represents the O.D. increase of 1 ul standard immunized
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Figure 111.18ELISA result on test group sera fromfish in tank #9
(7020 + 148 units/ml).The horizontal line represents
the O.D. increase of 1 ul standardimmunized serum which
was arbitrarilyassigned to be 1 antibody unit/ul.0.25 --:
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Figure 111.19ELISA result on test group sera from fish in tank #10
(14060 + 5580 units/ml). The horizontal line represents
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the O.D. increase of 1 ul standard immunized serum which
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was arbitrarily assigned to be 1 antibody unit/ul.173
serum antibody level was 333 (1000/3)units per ml for these
fish.
The bar chart in figure 111.20 shows the antibody
levels of 45 fish,(5 from each tank or 15 fish in each of
the test group, positive and negative controls).Fish in
the test group had significantly higher levels ofantibody
than both the positive and negative controls (p < 0.0001,
table 111.9).95 percent confidence intervals and Tukey's
HSD gave the same results (table III.10).
Mucus antibody levels
As pointed out in the previous section, the mucus
antibody levelswere too dilute to be detected.To make
the sample more concentrated, saturated ammonium sulfate
(SAS) was used to precipitate the protein contentsin mucus
samples.Because some mucus samples were contaminated with
fecal materials and the final sample volumes of mucus
collected were not exactly the same, antibody levelsin each
group were normalized on the basis ofprotein content.The
protein content of mucus samples was determined by Lowry's
protein assay method for the comparison.The calibration
curve of protein content is shown onfigure 111.21 using
bovine serum albumin as standard.Protein concentration of
mucus sample from each tank variedfrom 30 to 536 mcg/ml.
(figure 111.22).
During the ELISA of mucus, 1 ul of standard immunized
serum was again added to each ELISA plateto serve as a1E4
10007.
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Figure 111.20 Serum antibody levels of fish from tanks in different
groups (positive, negative controls and test).175
Table 111.9Analysis of Variancea on Serum Antibody Levels
Following Oral Vaccination { ln(antibody)}.
Source of Variation S.S. df M.S. F
Treatment 17.85 2 8.92 24.10
Between tanks 2.22 6 0.37 1.78
Error 7.49 36 0.21
Total 27.55 44
a ANOVA results was generated by a statistics software
called Statgraphics176
Table III.10Multiple Range Analysis for In (serum antibody
levels) by Group.
a. Method: 95 Percent Confidence Intervals
Level Count Average Homogeneous Groups
Negative 15 2.686 *
Positive 15 3.078 *
Test 15 4.173 *
b. Method: 95 Percent Tukey HSD Intervals
Level Count Average Homogeneous Groups
Negative 15 2.686 *
Positive 15 3.078 *
Test 15 4.173 *
*'s on the same vertical line represents homogeneous groups.0.5
0.4
0.3
0.2
0.1
R2= 0.999
0.0 z,illifi r*--1111---1----1 i
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Figure 111.21Calibration curve of protein concentration in fish
mucus using bovine serum albumin as standard.
Absorbance vs. concentration with line estimated from
linear regression.600
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Figure 111.22Protein concentrations in fish mucus from tanks in
different groups (positive, negative controls and test) .179
reference point. The whole standard curve was plotted in
figure 111.23 to ensure that 50% inhibition was given by
about 1 ul of standard immunized sera.
Figure 111.24 depicts the O.D. increase of mucus
samples from various tanks while figure 111.25 shows the
same result but the O.D. wasdivided by the O.D. given by 1
ul of standard immunized sera, which served as aninternal
standard for each ELISA plate.Results in each group were
pooled and the average calculated (figure 111.26). The
difference in antibody levels of each group are more easily
seen.Mucus antibody levels represented by sample
O.D. /standard O.D. were from 0.85 to 1.35 in thetest group,
0.75 to 0.95 in the positive control and 0.5 to 0.75for the
negative control group.Analysis of variance showed
significantly higher mucus antibody levels in the test group
(1.4 to 1.8 times greater) than both positive ornegative
controls (p < 0.001, table 111.11).The same results were
tested by multiple range analysis of 95 percentconfidence
intervals and Tukey's HSD intervals (table 111.12).
The results suggest that the newly developed oral
enteric coated vaccine can elicit good systemic and local
(mucosal) immune response.A significantly better immunity,
measured by higher serum and mucus antibody levels, was
observed in the test group.It also confirmed previous
findings that oral vaccine efficacy can be improved if the
vaccine can be protected from stomach acid degradation (23).
Because in vivo challenge of live bacteria could noto0 standard for tanks 2to 7
standard for tanks 8 to 10
0
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Figure 111.23ELISA standard curve obtained from standard immunized
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Figure 111.27Mucus antibody levels of fish from tanksin different
groups (positive, negativecontrols and test).185
Table 111.11Analysis of Variancea on O.D. Mucus Sample/
O.D. StandardFollowing Oral Vaccination.
Source of Variation S.S. df M.S. F
Treatments 0.776 2 0.388 24.59
Between tanks 0.023 6 0.004 0.24
In (protein content)0.052 4 0.013 0.82
Error 0.331 21 0.016
Total 1.280 33
a ANOVA results was generated by a statistics software
called Statgraphics186
Table 111.12Multiple Range Analysis for O.D. Mucus Sample/
O.D. Standard by Group.
a. Method: 95 Percent Confidence Intervals
Level Count Average
Negative 10 0.687
Positive 11 0.875
Test 13 1.078
b. Method: 95 Percent Tukey HSD Intervals
Level Count Average
Negative 10 0.687
Positive 11 0.875
Test 13 1.078
Homogeneous Groups
*
*
*
Homogeneous Groups
*
*
*
*'s on the same vertical line represents homogeneous groups.187
distinguish any difference between the test group and
positive controls, the conclusions made from total
mortalities or survival rates may not be a good end point to
indicate vaccine efficacy.This may be the reason why
opposite results were observed by Lillehaug in 1989 (25) and
Johnson & Amend in 1983 (23).
Johnson & Amend (23) administered their suspension
vaccine by anal intubation and found better survival rates
among these vaccinated fish than fish that were given the
vaccine orally.On the other hand, Lillehaug (25) concluded
his slow-release pellet and enteric coated granule vaccines
to be less efficacious than unprotected vaccines when they
were administered orally.The size of Lillehaug's vaccines
was in the range of 1 to 2 mm and each fish had an average
weight of 50 g.As pointed out in chapter I of this thesis,
the average diameter of the pyloric sphincter is 0.94 mm +
0.12 mm.It is very likely that Lillehaug's vaccine beads
took a long time to pass through to the pyloric sphincter
into the pyloric caeca.If the vaccine time of residence in
the stomach was too great, the vaccine may have been
released in the stomach instead of the intestine as thought.
To develop a successful oral vaccine, protection of the
antigen against possible degradation in the stomach must be
achieved while later having the vaccine released rapidly
into the intestine where absorption and interaction with the
immune system can occur.In this thesis dissolution
experiments were performed on all vaccines developed using188
both USP simulated gastric (26) and intestinal (27) fluids
without enzymes to determine the optimum levels of VA LS 1-
74 loading and thickness of enteric coating for acid
protection and rapid release in the second gut.This type
of study is routinely done in the pharmaceutical industry
and requested by the Food and Drug Administration (FDA) for
drug approvals (28).
It is true that lipopolysaccharide from Vibrio
anguillarum cell walls is the major antigen for protection
against vibriosis (13,29) and may not be subject to acid
degradation in the stomach.However, it is desirable for
the vaccine to be deposited in the second gut where antigens
are processed and interaction with the immune response
occurs (19,20,21).Slow-release prills or enteric coated
granules prepared by Lillehaug were less efficacious than
unprotected vaccines because of decreased antigen absorption
as explained by the author.On the other hand, the vaccine
developed here has both the characteristics of enteric
protection and rapid release in the intestine.Therefore,
it generated better immune response than unprotected
vaccine.
The prospect of an oral enteric protected vaccine can
be very promising.First of all, similar vaccines can be
made to control enteric red mouth or furunculosis, where
commercially available vaccines are administered by
immersion but are not effective when given orally.
Secondly, this method of preparing oral vaccine is189
especially applicable when the major antigen is protein and
will denature in an acidic environment.Last but not least,
it can be applied to formulate vaccines for human or other
animal use.Up till the end of 1989, there was only one
oral vaccine for human use, which is inactivated poliovirus
vaccine.Early this year, the second oral human vaccine,
live oral typhoid vaccine Ty2la in the form of enteric
capsules, was approved by the FDA (30).Oral vaccines are
actively being developed for many human and animal diseases
such as influenza (31,32,33) or rabies (34).190
CONCLUSIONS
In vivo studies have shown that our enteric coated oral
Vibrio vaccine can provide protection against live bacteria
challenge.Furthermore, both mucosal (integumentary) and
systemic immune responses were elicited.Also, serum and
mucosal antibody levels may be better indicators of the
effectiveness of a vaccine during an in vivo challenge than
survival rate.
Application of this technique of loading of the antigen
on non-pareil sugar beads and enteric coating the antigen to
formulate other oral vaccines for animal or human diseases
is promising.Also, other protein drug moieties can be
delivered in the same manner if they are susceptible to
destruction in the acidic environment of the stomach.So
far, no vaccine exists for the bacterial kidney disease
caused by Renibacterium salmoninarum in salmonids.However,
a soluble antigen has been identified (35) and it can be
used as the next prototype antigen for this vaccine delivery
system.
Future research should include:
Determination of the size of fish that would be used
in vaccination trials.As has been shown, a major factor
for the success of oral vaccine is the size of the pyloric
sphincter.It prohibits the passage of large particles to
the pyloric caeca.
Identification of a suitable carrier to load the191
antigens onto.Non-pareil sugar beads of mesh size 18-20
were used in this project.When smaller fish are used, a
smaller carrier bead will be needed for the surface to load
the vaccine on.
Choosing a prototype antigen (BSA or other proteins)
and development of an ELISA for antibodies against that
antigen.Serum and mucosal antibodies levels should always
be used to indicate the effectiveness of future oral
vaccines.
Spray coat the antigen on carriers and apply an
enteric coating on top to serve as a protection against
stomach acid.Find out the optimum coating conditions.
Run in vitro dissolution studies on formulated
vaccines.Determine whether antigens undergo any
degradation or denaturation and determine the best
combination of levels of enteric coating and antigen loading
for enteric protection and rapid release.
Establish a dose-response curve to determine the
optimum levels of antigen in carriers (non-pareil sugar
beads?).
Choose the best formulation(s) and run in vivo
challenge of live bacteria.Determine and compare serum,
mucosal antibody levels (a) before the vaccination
procedure,(b) after the vaccination procedure but before
the in vivo challenge and (c) after the in vivo challenge.
Run statistical analysis on antibody levels and
mortalities to conclude the effectiveness.192
ENDNOTES
1See chapter II for exact procedure.
2Courtesy of Dr. Jerry D Hendricks, Professor of Food
Science and Technology, Food Toxicology and Nutrition
Laboratory, Oregon State University, Corvallis, OR
3 The Sigma Chemical Company, St. Louis, Missouri, U.S.A.
4 The Sigma Chemical Company, St. Louis, Missouri, U.S.A.
5 The Sigma Chemical Company, St. Louis, Missouri, U.S.A.
6The Sigma Chemical Company, St. Louis, Missouri, U.S.A.
7Costar ELISA plate, #3590, Cambridge, Massachusetts,
U.S.A.
8Autoreader Model EL 310, Bio-Tek Instruments, Inc.,
Burlington, Vermont, U.S.A.
9Beckman Microfuge ETM, Spinco Division, Palo Alto,
California, U.S.A.
10 SorvallRRC-5B Refrigerated Super Speed Centrifuge,
DuPont Instruments
11see Table II.a
12 The Sigma Chemical Company, St. Louis, Missouri, U.S.A.
13Beckman Model T J-6 Centrifuge, Palo Alto, California,
U.S.A.193
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